CUMULATIVE
SUPPLEMENT 5
MAY 2002



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

22nd EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Information Technology
Division of Data Management and Services

2002

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

22ND EDITION

Cumulative Supplement 5

May 2002

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

22ND EDITION

CUMULATIVE SUPPLEMENT 5
MAY 2002

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 22nd Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 22nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 23rd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated

*U.S. Government Printing Office: 2002 — 491-214/40013

Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
DANBURY PHARMACEUTICALS INC (DANBURY PHARMA)	WATSON LABORATORIES INC (WATSON LABS)
DURAMED PHARMACEUTICALS INC (DURAMED)	DURAMED PHARMACEUTICALS INC SUB OF BARR LABORATORIES INC (DURAMED PHARM BARR)
DERMIK LABORATORIES INC (DERMIK LABS)	DERMIK LABORATORIES DIVISION OF AVENTIS PHARMACEUTICALS INC (DERMIK LABS)
DERMIK LABORATORIES INC SUB RORER (DERMIK LABS)	DERMIK LABORATORIES DIVISION OF AVENTIS PHARMACEUTICALS INC (DERMIK LABS)
McNEIL CONSUMER HEALTHCARE DIVISION (McNEIL CONS)	McNEIL CONSUMER AND SPECIALTY PHARMACEUTICALS DIVISION McNEIL PPC (McNEIL CONS SPECLT)
WHITEHALL LABORATORIES INC DIV AMERICAN HOME PRODUCTS CORP (WHITEHALL LABS)	WYETH CONSUMER HEALTHCARE (WYETH CONS)
WHITEHALL ROBINS HEALTHCARE (WHITEHALL ROBINS)	WYETH CONSUMER HEALTHCARE (WYETH CONS)
WHITEHALL ROBINS HEALTHCARE DIV AMERICAN HOME PRODUCTS CORP (WHITEHALL LABS)	WYETH CONSUMER HEALTHCARE (WYETH CONS)

1.3 AVAILABILITY OF THE EDITION

The 22nd Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $105.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at
http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 22nd annual edition of the 2001 Orange Book Patent and Exclusivity List is at
http://www.fda.gov/cder/orange/22bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at
http://www.fda.gov/cder/orange/docket.pdf. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.html

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2001) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2001	MAR 2002	JUN 2002	SEP 2002
DRUG PRODUCTS LISTED	10166	10357		
SINGLE SOURCE	2665 26.2%)	2645 (25.5%)		
MULTISOURCE	7391 72.7%)	7602 (73.4%)		
THERAPEUTICALLY EQUIVALENT	7105 69.9%)	7309 (70.6%)		
NOT THERAPEUTICALLY EQUIVALENT	286 (2.8%)	293 (2.8%)		
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)		
NEW MOLECULAR ENTITIES APPROVED	10	1		
NUMBER OF APPLICANTS	574	574		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form;Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form;route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

		ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE							
		CAPSULE; ORAL							
		ACETAMINOPHEN, BUTALBITAL, CAFFEINE, AND CODEINE PHOSPHATE							
	AB	VINTAGE PHARMS	325MG;50MG;40MG;30MG		N75929 001	APR 22, 2002	APR	NEWA
		ACETAMINOPHEN; CODEINE PHOSPHATE							
		CAPSULE; ORAL							
>D>		PHENAPHEN W/ CODEINE NO. 2							
>D>		+ ROBINS AH	325MG;15MG		N84444 001		MAY	DISC
>A>		@	325MG;15MG		N84444 001		MAY	DISC
		SOLUTION; ORAL							
		ACETAMINOPHEN AND CODEINE PHOSPHATE							
>D>	AA	ALPHARMA	120MG/5ML;12MG/5ML		N85861 001		MAY	CRLD
>A>	AA	+	120MG/5ML;12MG/5ML		N85861 001		MAY	CRLD
>D>		TYLENOL W/ CODEINE							
>D>	AA	+ JOHNSON RW	120MG/5ML;12MG/5ML		N85057 001		MAY	DISC
>A>		@	120MG/5ML;12MG/5ML		N85057 001		MAY	DISC
		TABLET; ORAL							
		ACETAMINOPHEN AND CODEINE PHOSPHATE							
>D>	AA	PUREPAC PHARM	300MG;60MG		N86683 001		MAY	DISC
>A>		@	300MG;60MG		N86683 001		MAY	DISC
		ACETAMINOPHEN; HYDROCODONE BITARTRATE							
		SOLUTION; ORAL							
		HYDROCODONE BITARTRATE AND ACETAMINOPHEN							
	AA	KV PHARM	500MG/15ML;7.5MG/15ML		N40366 001	JAN 23, 2002	JAN	NEWA
		TABLET; ORAL							
		NORCO							
>D>	AA	+ WATSON LABS	325MG;5MG		N40099 001	JUN 25, 1997	MAY	CTNA
>A>	AA	+	325MG;5MG		N40099 001	JUN 25, 1997	MAY	CTNA
		ALBUTEROL SULFATE							
		AEROSOL, METERED; INHALATION							
		PROVENTIL-HFA							
	BX	+ 3M	EQ 0.09MG BASE/INH		N20503 001	AUG 15, 1996	MAR	CTEC
		VENTOLIN HFA							
	BX	+ GLAXOSMITHKLINE	EQ 0.09MG BASE/INH		N20983 001	APR 19, 2001	MAR	CTEC
		ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE							
		INJECTABLE; INJECTION							
		MULTI-12							
		+ SABEX 2002	2 IU/ML;20MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;80UGM/ML;8MG/ML;0.8MG/ML;0.72MG/ML;0.6MG/ML;600 IU/ML		N21163 001	MAY 18, 2000	APR	CAHN
		AMMONIUM LACTATE							
		CREAM; TOPICAL							
>A>		AMMONIUM LACTATE							
>A>	AB	CLAY PARK	EQ 12% BASE		N75774 001	MAY 01, 2002	MAY	NEWA

		AMMONIUM LACTATE							
		CREAM; TOPICAL							
		LAC-HYDRIN							
>D>		+ WESTWOOD SQUIBB	EQ 12% BASE	N20508 001	AUG 29, 1996	MAY	CFTG		
>A>	AB	+	EQ 12% BASE	N20508 001	AUG 29, 1996	MAY	CFTG		
		AMOXICILLIN; CLAVULANATE POTASSIUM							
		FOR SUSPENSION; ORAL							
		AUGMENTIN '400'							
		GLAXOSMITHKLINE	400MG/5ML;EQ 57MG BASE/5ML	N50725 002	MAY 31, 1996	FEB	CRLD		
		TABLET; ORAL							
		AMOXICILLIN AND CLAVULANATE POTASSIUM							
	AB	GENEVA PHARMS	500MG;EQ 125MG BASE	N65064 001	MAR 15, 2002	MAR	NEWA		
	AB		875MG;EQ 125MG BASE	N65063 001	MAR 14, 2002	MAR	NEWA		
		AUGMENTIN '500'							
	AB	GLAXOSMITHKLINE	500MG;EQ 125MG BASE	N50564 002	AUG 06, 1984	MAR	CFTG		
		AUGMENTIN '875'							
	AB	+ GLAXOSMITHKLINE	875MG;EQ 125MG BASE	N50720 001	FEB 13, 1996	MAR	CFTG		
		TABLET, CHEWABLE; ORAL							
		AMOXICILLIN AND CLAVULANATE POTASSIUM							
	AB	GENEVA PHARMS	200MG;EQ 28.5MG BASE	N65065 001	APR 18, 2002	APR	NEWA		
	AB		400MG;EQ 57MG BASE	N65065 002	APR 18, 2002	APR	NEWA		
		AUGMENTIN '200'							
	AB	GLAXOSMITHKLINE	200MG;EQ 28.5MG BASE	N50726 001	MAY 31, 1996	APR	CFTG		
		AUGMENTIN '400'							
	AB	+ GLAXOSMITHKLINE	400MG;EQ 57MG BASE	N50726 002	MAY 31, 1996	APR	CFTG		
		AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE							
		TABLET; ORAL							
		ADDERALL 10							
	AB	SHIRE LABS	2.5MG;2.5MG;2.5MG;2.5MG	N11522 007	FEB 13, 1996	FEB	CFTG		
		ADDERALL 20							
	AB	SHIRE LABS	5MG;5MG;5MG;5MG	N11522 008	FEB 13, 1996	FEB	CFTG		
		ADDERALL 30							
	AB	+ SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N11522 010	MAY 12, 1997	FEB	CFTG		
		ADDERALL 5							
	AB	SHIRE LABS	1.25MG;1.25MG;1.25MG;1.25MG	N11522 009	MAY 12, 1997	FEB	CFTG		
		DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE							
	AB	BARR	1.25MG;1.25MG;1.25MG;1.25MG	N40422 001	FEB 11, 2002	FEB	NEWA		
	AB		2.5MG;2.5MG;2.5MG;2.5MG	N40422 002	FEB 11, 2002	FEB	NEWA		
	AB		5MG;5MG;5MG;5MG	N40422 003	FEB 11, 2002	FEB	NEWA		
	AB		7.5MG;7.5MG;7.5MG;7.5MG	N40422 004	FEB 11, 2002	FEB	NEWA		
		AMPHOTERICIN B							
		INJECTABLE, LIPID COMPLEX; INJECTION							
		ABELCET							
		+ ELAN PHARMS	5MG/ML	N50724 001	NOV 20, 1995	JAN	CAHN		
		AMPICILLIN SODIUM; SULBACTAM SODIUM							
		INJECTABLE; INJECTION							
		AMPICILLIN AND SULBACTAM							
	AP	ESI LEDERLE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N65074 001	MAR 19, 2002	MAR	NEWA		

	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N65074 002	MAR 19, 2002	MAR	NEWA
	AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N65076 001	MAR 19, 2002	MAR	NEWA
		UNASYN					
	AP	+ PFIZER	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N50608 002	DEC 31, 1986	MAR	CFTG
	AP	+	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N50608 001	DEC 31, 1986	MAR	CFTG
	AP	+	EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N50608 005	DEC 10, 1993	MAR	CFTG
	AMPRENAVIR						
>D>	CAPSULE; ORAL						
>D>	AGENERASE						
>D>	GLAXOSMITHKLINE		50MG	N21007 001	APR 15, 1999	MAY	DISC
>A>	@		50MG	N21007 001	APR 15, 1999	MAY	DISC
>D>	+		150MG	N21007 002	APR 15, 1999	MAY	DISC
>A>	@		150MG	N21007 002	APR 15, 1999	MAY	DISC
>D>	SOLUTION; ORAL						
>D>	AGENERASE						
>D>	+ GLAXOSMITHKLINE		15MG/ML	N21039 001	APR 15, 1999	MAY	DISC
>A>	@		15MG/ML	N21039 001	APR 15, 1999	MAY	DISC
	ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K						
	INJECTABLE; IV (INFUSION)						
	INFUVITE PEDIATRIC						
	+ SABEX 2002		80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21265 001	FEB 21, 2001	APR	CAHN
	ATROPINE; PRALIDOXIME CHLORIDE						
	INJECTABLE; INTRAMUSCULAR						
	ATNAA						
	+ @ US ARMY		2.1MG/0.7ML;600MG/2ML	N21175 001	JAN 17, 2002	JAN	NEWA
	@		2.1MG/0.7ML;600MG/2ML	N21175 001	JAN 17, 2002	FEB	NEWA
	AZELASTINE HYDROCHLORIDE						
	SOLUTION/DROPS; OPHTHALMIC						
	OPTIVAR						
>D>	+ ASTA		0.05%	N21127 001	MAY 22, 2000	MAY	CAHN
>A>	+ MURO		0.05%	N21127 001	MAY 22, 2000	MAY	CAHN
	AZITHROMYCIN DIHYDRATE						
	TABLET; ORAL						
	ZITHROMAX						
>A>	+ PFIZER		EQ 500MG BASE	N50784 001	MAY 24, 2002	MAY	NEWA
	BACITRACIN ZINC; POLYMYXIN B SULFATE						
	OINTMENT; OPHTHALMIC						
	BACITRACIN ZINC AND POLYMYXIN B SULFATE						
AT	ALTANA		500 UNITS/GM;10,000 UNITS/GM	N65022 001	FEB 27, 2002	FEB	NEWA

BENZONATATE
CAPSULE; ORAL
TESSALON

	+	FOREST LABS	200MG	N11210 003	JUN 25, 1999	MAR	NEWA

BENZTROPINE MESYLATE
TABLET; ORAL
BENZTROPINE MESYLATE

>A>	AA	COREPHARMA	0.5MG	N72264 001	FEB 27, 1989	MAY	CAHN
>A>	AA		1MG	N72265 001	FEB 27, 1989	MAY	CAHN
>A>	AA		2MG	N72266 001	FEB 27, 1989	MAY	CAHN
>D>	AA	GENEVA PHARMS TECH	0.5MG	N72264 001	FEB 27, 1989	MAY	CAHN
>D>	AA		1MG	N72265 001	FEB 27, 1989	MAY	CAHN
>D>	AA		2MG	N72266 001	FEB 27, 1989	MAY	CAHN

BROMOCRIPTINE MESYLATE
TABLET; ORAL
BROMOCRIPTINE MESYLATE

AB	LEK SVCS	EQ 2.5MG BASE	N74631 001	JAN 13, 1998	JAN	CMFD
	PARLODEL					
AB	+ NOVARTIS	EQ 2.5MG BASE	N17962 001		JAN	CFTG

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE
SYRUP; ORAL
BROMANYL

>D>	AA	ALPHARMA	12.5MG/5ML;10MG/5ML	N88343 001	AUG 15, 1984	MAY	DISC
>A>		@	12.5MG/5ML;10MG/5ML	N88343 001	AUG 15, 1984	MAY	DISC

BUPIVACAINE HYDROCHLORIDE
INJECTABLE; INJECTION
BUPIVACINE HCL PRESERVATIVE FREE

AP	INTL MEDICATED	0.25%	N76012 001	JAN 09, 2002	JAN	NEWA
AP		0.5%	N76012 002	JAN 09, 2002	JAN	NEWA
AP		0.75%	N76012 003	JAN 09, 2002	JAN	NEWA

BUSPIRONE HYDROCHLORIDE
TABLET; ORAL
BUSPIRONE HCL

AB	EGIS	5MG	N75119 001	MAR 14, 2002	MAR	NEWA
AB		10MG	N75119 002	MAR 14, 2002	MAR	NEWA
AB	GENEVA PHARMS	5MG	N75413 001	MAR 19, 2002	MAR	NEWA
AB		10MG	N75413 002	MAR 19, 2002	MAR	NEWA
AB		15MG	N75413 003	MAR 19, 2002	MAR	NEWA
AB	KV PHARM	5MG	N75572 001	FEB 27, 2002	FEB	NEWA
AB		10MG	N75572 002	FEB 27, 2002	FEB	NEWA
AB		15MG	N75572 003	FEB 27, 2002	FEB	NEWA
AB	MYLAN	5MG	N75272 001	MAR 01, 2002	MAR	NEWA
AB		10MG	N75272 002	MAR 01, 2002	MAR	NEWA
>A>	AB		30MG	N76008 001	JUN 28, 2001	MAY	CAHN
>D>	AB	MYLAN TECHNOLOGIES	30MG	N76008 001	JUN 28, 2001	MAY	CAHN
AB	PAR PHARM	5MG	N75467 001	FEB 28, 2002	FEB	NEWA
AB		10MG	N75467 003	FEB 28, 2002	FEB	NEWA

	AB		15MG	N75467 004	FEB 28, 2002	FEB	NEWA
>A>	AB	PHARMEX PRODS	5MG	N75388 001	MAY 09, 2002	MAY	NEWA
>A>	AB		10MG	N75388 002	MAY 09, 2002	MAY	NEWA
>A>	AB		15MG	N75388 003	MAY 09, 2002	MAY	NEWA
	AB	TEVA	5MG	N75022 001	FEB 28, 2002	FEB	NEWA
	AB		10MG	N75022 002	FEB 28, 2002	FEB	NEWA
	AB		15MG	N75022 003	FEB 28, 2002	FEB	NEWA
	AB	TORPHARM	5MG	N75521 001	APR 05, 2002	APR	NEWA
	AB		10MG	N75521 002	APR 05, 2002	APR	NEWA
	AB		15MG	N75521 003	APR 05, 2002	APR	NEWA
	AB	ZENITH GOLDLINE	5MG	N75385 001	MAR 01, 2002	MAR	NEWA
	AB		10MG	N75385 002	MAR 01, 2002	MAR	NEWA
	AB		15MG	N75385 003	MAR 01, 2002	MAR	NEWA

BUTORPHANOL TARTRATE
SPRAY, METERED; NASAL
BUTORPHANOL TARTRATE

AB	ROXANE	1MG/SPRAY	N75824 001	MAR 12, 2002	MAR	NEWA

CALCIPOTRIENE
OINTMENT; TOPICAL
DOVONEX

+	BRISTOL MYERS SQUIBB	0.005%	N20273 001	DEC 29, 1993	FEB	CAHN

SOLUTION; TOPICAL

+	BRISTOL MYERS SQUIBB	0.005%	N20611 001	MAR 03, 1997	FEB	CAHN

CAPTOPRIL
TABLET; ORAL
CAPOTEN

>D>	AB	BRISTOL MYERS SQUIBB	12.5MG	N18343 005	JAN 17, 1985	MAY	CAHN
>D>	AB		25MG	N18343 002		MAY	CAHN
>D>	@		37.5MG	N18343 006	SEP 17, 1986	MAY	CAHN
>D>	AB		50MG	N18343 001		MAY	CAHN
>D>	@		75MG	N18343 007	JUN 13, 1995	MAY	CAHN
>D>	AB +		100MG	N18343 003		MAY	CAHN
>D>	@		150MG	N18343 004	JUN 13, 1995	MAY	CAHN
>A>	AB	PAR PHARM	12.5MG	N18343 005	JAN 17, 1985	MAY	CAHN
>A>	AB		25MG	N18343 002		MAY	CAHN
>A>	@		37.5MG	N18343 006	SEP 17, 1986	MAY	CAHN
>A>	AB		50MG	N18343 001		MAY	CAHN
>A>	@		75MG	N18343 007	JUN 13, 1995	MAY	CAHN
>A>	AB +		100MG	N18343 003		MAY	CAHN
>A>	@		150MG	N18343 004	JUN 13, 1995	MAY	CAHN

CARBAMAZEPINE
TABLET; ORAL
CARBAMAZEPINE

AB	APOTEX	200MG	N75948 001	FEB 27, 2002	FEB	NEWA

CARTEOLOL HYDROCHLORIDE
SOLUTION/DROPS; OPHTHALMIC
CARTEOLOL HCL

AT	NOVEX	1%	N76097 001	FEB 06, 2002	FEB	NEWA

			CEFADROXIL/CEFADROXIL HEMIHYDRATE					
			CAPSULE; ORAL					
			DURICEF					
>D>			@ BRISTOL MYERS SQUIBB	EQ 250MG BASE	N50512 002		MAY	CAHN
>A>			@ GALEN CHEM	EQ 250MG BASE	N50512 002		MAY	CAHN
			FOR SUSPENSION; ORAL					
>D>			BRISTOL MYERS SQUIBB	EQ 125MG BASE/5ML	N50527 002		MAY	CAHN
>D>				EQ 250MG BASE/5ML	N50527 003		MAY	CAHN
>D>		+		EQ 500MG BASE/5ML	N50527 001		MAY	CAHN
>A>			GALEN CHEM	EQ 125MG BASE/5ML	N50527 002		MAY	CAHN
>A>				EQ 250MG BASE/5ML	N50527 003		MAY	CAHN
>A>		+		EQ 500MG BASE/5ML	N50527 001		MAY	CAHN
			TABLET; ORAL					
>D>	AB	+	BRISTOL MYERS SQUIBB	EQ 1GM BASE	N50528 001		MAY	CAHN
>A>	AB	+	GALEN CHEM	EQ 1GM BASE	N50528 001		MAY	CAHN
			CEFPODOXIME PROXETIL					
			FOR SUSPENSION; ORAL					
>A>			CEFPODOXIME PROXETIL					
>A>	AB		RANBAXY	EQ 50MG BASE/5ML	N65082 001	MAY 31, 2002	MAY	NEWA
>A>	AB			EQ 100MG BASE/5ML	N65082 002	MAY 31, 2002	MAY	NEWA
			VANTIN					
>D>			PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML	N50675 001	AUG 07, 1992	MAY	CFTG
>A>	AB			EQ 50MG BASE/5ML	N50675 001	AUG 07, 1992	MAY	CFTG
>D>		+		EQ 100MG BASE/5ML	N50675 002	AUG 07, 1992	MAY	CFTG
>A>	AB	+		EQ 100MG BASE/5ML	N50675 002	AUG 07, 1992	MAY	CFTG
			CEFUROXIME AXETIL					
			TABLET; ORAL					
			CEFTIN					
	AB		GLAXOSMITHKLINE	EQ 125MG BASE	N50605 001	DEC 28, 1987	FEB	CFTG
	AB			EQ 250MG BASE	N50605 002	DEC 28, 1987	FEB	CFTG
	AB	+		EQ 500MG BASE	N50605 003	DEC 28, 1987	FEB	CFTG
			CEFUROXIME AXETIL					
	AB		RANBAXY	EQ 125MG BASE	N65043 003	FEB 15, 2002	FEB	NEWA
	AB			EQ 250MG BASE	N65043 002	FEB 15, 2002	FEB	NEWA
	AB			EQ 500MG BASE	N65043 001	FEB 15, 2002	FEB	NEWA
			CEPHALEXIN					
			FOR SUSPENSION; ORAL					
			CEPHALEXIN					
			@ TEVA	EQ 125MG BASE/5ML	N62873 001	MAY 23, 1988	APR	DISC
			@	EQ 250MG BASE/5ML	N62867 001	APR 15, 1988	APR	DISC
			CEPHALOGLYCIN					
			CAPSULE; ORAL					
>D>			KAFOCIN					
>D>		+	LILLY	250MG	N50219 001		MAY	DISC
>A>		+	@	250MG	N50219 001		MAY	DISC

CERIVASTATIN SODIUM
TABLET; ORAL
BAYCOL

		@ BAYER	0.2MG	N20740	003	JUN 26, 1997	JAN	DISC
		@	0.3MG	N20740	004	JUN 26, 1997	JAN	DISC
		@	0.4MG	N20740	005	MAY 24, 1999	JAN	DISC
		@	0.8MG	N20740	006	JUL 24, 2000	JAN	DISC

CHLORPROPAMIDE
TABLET; ORAL
CHLORPROPAMIDE

>D>	AB	LEDERLE	100MG	N89561	001	SEP 04, 1987	MAY	DISC
>A>		@	100MG	N89561	001	SEP 04, 1987	MAY	DISC
>D>	AB		250MG	N89562	001	SEP 04, 1987	MAY	DISC
>A>		@	250MG	N89562	001	SEP 04, 1987	MAY	DISC

CHORIOGONADOTROPIN ALFA
INJECTABLE; INJECTION
OVIDREL

		+ SERONO INC	0.25MG/VIAL	N21149	001	SEP 20, 2000	FEB	CAHN

CIMETIDINE
TABLET; ORAL
CIMETIDINE

	AB	LEK LJUBLJANA	300MG	N74250	002	JUN 29, 1995	FEB	CMFD
	AB		400MG	N74250	003	JUN 29, 1995	FEB	CMFD
	AB		800MG	N74250	004	JUN 29, 1995	FEB	CMFD

CLADRIBINE
INJECTABLE; INJECTION
LEUSTATIN

		+ ORTHO BIOTECH	1MG/ML	N20229	001	FEB 26, 1993	MAR	CAHN

CLINDAMYCIN PHOSPHATE
LOTION; TOPICAL
CLEOCIN T

	AB	+ PHARMACIA AND UPJOHN	EQ 1% BASE	N50600	001	MAY 31, 1989	JAN	CFTG

CLINDAMYCIN PHOSPHATE

	AB	ALTANA	EQ 1% BASE	N65067	001	JAN 31, 2002	JAN	NEWA

SWAB; TOPICAL

	AT	CLAY PARK	EQ 1% BASE	N65049	001	MAY 25, 2000	FEB	CDFR

CLOBETASOL PROPIONATE
GEL; TOPICAL
EMBELINE

	AB	HEALTHPOINT	0.05%	N76141	001	APR 12, 2002	APR	NEWA

CLOZAPINE
TABLET; ORAL
CLOZARIL

>D>	AB	+ NOVARTIS	25MG	N19758	001	SEP 26, 1989	MAY	CRLD
>A>	AB		25MG	N19758	001	SEP 26, 1989	MAY	CRLD

>D>	AB		100MG	N19758 002	SEP 26, 1989	MAY	CRLD
>A>	AB +		100MG	N19758 002	SEP 26, 1989	MAY	CRLD

CROMOLYN SODIUM
SOLUTION; INHALATION
CROMOLYN SODIUM

AN		NOVEX	10MG/ML	N75333 001	APR 30, 2002	APR	NEWA

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58
N/A; N/A
DICOPAC KIT

@	AMERSHAM HLTH		N/A;N/A;N/A	N17406 001		FEB	DISC

CYCLOSPORINE
CAPSULE; ORAL
CYCLOSPORINE

>D>	AB	ABBOTT	25MG	N65003 001	MAY 12, 2000	MAY	CTEC
>A>	AB1		25MG	N65003 001	MAY 12, 2000	MAY	CTEC
>D>			50MG	N65003 002	MAY 12, 2000	MAY	CTEC
>A>	BX		50MG	N65003 002	MAY 12, 2000	MAY	CTEC
>D>	AB1		100MG	N65003 003	MAY 12, 2000	MAY	CTEC
>A>	AB1		100MG	N65003 003	MAY 12, 2000	MAY	CTEC
>D>	AB	EON	25MG	N65017 002	JAN 13, 2000	MAY	CTEC
>A>	AB1		25MG	N65017 002	JAN 13, 2000	MAY	CTEC
>D>	AB		100MG	N65017 001	JAN 13, 2000	MAY	CTEC
>A>	AB1		100MG	N65017 001	JAN 13, 2000	MAY	CTEC
>D>	AB	SIDMAK LABS	25MG	N65044 002	DEC 20, 2000	MAY	CTEC
>A>	AB1		25MG	N65044 002	DEC 20, 2000	MAY	CTEC
>D>	AB		100MG	N65044 001	DEC 20, 2000	MAY	CTEC
>A>	AB1		100MG	N65044 001	DEC 20, 2000	MAY	CTEC
>A>	AB2	TORPHARM	25MG	N65040 001	MAY 09, 2002	MAY	CTEC
>A>	AB2		100MG	N65040 002	MAY 09, 2002	MAY	NEWA
>D>			25MG	N65040 001	MAY 09, 2002	MAY	CTEC

NEORAL

>D>	AB	NOVARTIS	25MG	N50715 001	JUL 14, 1995	MAY	CTEC
>A>	AB1		25MG	N50715 001	JUL 14, 1995	MAY	CTEC
>D>	AB +		100MG	N50715 002	JUL 14, 1995	MAY	CTEC
>A>	AB1 +		100MG	N50715 002	JUL 14, 1995	MAY	CTEC

SANDIMMUNE

>D>	BX	NOVARTIS	25MG	N50625 001	MAR 02, 1990	MAY	CTEC
>A>	AB2		25MG	N50625 001	MAR 02, 1990	MAY	CTEC
>D>	BX +		100MG	N50625 002	MAR 02, 1990	MAY	CTEC
>A>	AB2 +		100MG	N50625 002	MAR 02, 1990	MAY	CTEC

SOLUTION; ORAL
CYCLOSPORINE

AB		ABBOTT	100MG/ML	N65025 001	MAR 03, 2000	JAN	CMFD

DEFEROXAMINE MESYLATE
INJECTABLE; INJECTION
DESFERAL

+		NOVARTIS	2GM/VIAL	N16267 002	MAY 25, 2000	FEB	CPOT

DESMOPRESSIN ACETATE
SPRAY, METERED; NASAL

>D>			DDAVP					
>D>	AB	+	AVENTIS	0.01MG/SPRAY	N17922 002	FEB 06, 1989	MAY	DISC
>A>			@	0.01MG/SPRAY	N17922 002	FEB 06, 1989	MAY	DISC
			DESMOPRESSIN ACETATE					
>D>	AB		BAUSCH AND LOMB	0.01MG/SPRAY	N74830 001	JAN 25, 1999	MAY	CRLD
>A>	AB	+		0.01MG/SPRAY	N74830 001	JAN 25, 1999	MAY	CRLD

DESOGESTREL; ETHINYL ESTRADIOL
TABLET; ORAL-28

			KARIVA					
	AB		BARR	0.15MG;0.02MG;0.01MG	N75863 001	APR 05, 2002	APR	NEWA
			MIRCETTE					
	AB	+	ORGANON	0.15MG;0.02MG;0.01MG	N20713 001	APR 22, 1998	APR	CFTG

DESONIDE
LOTION; TOPICAL

			DESONIDE					
	AB		ALTANA	0.05%	N75860 001	MAR 19, 2002	MAR	NEWA
			DESOWEN					
	AB	+	GALDERMA LABS LP	0.05%	N72354 001	JAN 24, 1992	MAR	CFTG

DESOXIMETASONE
OINTMENT; TOPICAL

			DESOXIMETASONE					
>D>	AB		ALTANA	0.25%	N73440 001	APR 01, 1998	MAY	DISC
>A>			@	0.25%	N73440 001	APR 01, 1998	MAY	DISC

DEXAMETHASONE ACETATE
INJECTABLE; INJECTION

			DECADRON-LA					
			@ MERCK	EQ 8MG BASE/ML	N16675 001		APR	DISC
			DEXAMETHASONE ACETATE					
			@ STERIS	EQ 8MG BASE/ML	N84315 001		APR	DISC
			@	EQ 16MG BASE/ML	N87711 001	MAY 24, 1982	APR	DISC

DEXTROAMPHETAMINE SULFATE
CAPSULE, EXTENDED RELEASE; ORAL

			DEXEDRINE					
	AB	+	GLAXOSMITHKLINE	5MG	N17078 001		JAN	CFTG
	AB	+		10MG	N17078 002		JAN	CFTG
	AB	+		15MG	N17078 003		JAN	CFTG
			DEXTROAMPHETAMINE SULFATE					
	AB		BARR	5MG	N76137 001	JAN 18, 2002	JAN	NEWA
	AB			10MG	N76137 002	JAN 18, 2002	JAN	NEWA
	AB			15MG	N76137 003	JAN 18, 2002	JAN	NEWA
			TABLET; ORAL					
	AA		MALLINCKRODT	5MG	N40436 001	JAN 29, 2002	JAN	NEWA
	AA			10MG	N40436 002	JAN 29, 2002	JAN	NEWA

DICLOFENAC POTASSIUM
TABLET; ORAL
DICLOFENAC POTASSIUM

AB	MUTUAL PHARM	50MG	N75470 001	FEB 21, 2002	FEB	NEWA	

DICLOFENAC SODIUM
TABLET, DELAYED RELEASE; ORAL
DICLOFENAC SODIUM

AB	ALPHAPHARM	50MG	N75281 002	FEB 12, 2002	FEB	NEWA	
AB		75MG	N75281 003	FEB 12, 2002	FEB	NEWA	

TABLET, EXTENDED RELEASE; ORAL

AB	PUREPAC PHARM	100MG	N75910 001	JAN 07, 2002	JAN	NEWA	

DILTIAZEM HYDROCHLORIDE
INJECTABLE; INJECTION
DILTIAZEM HCL

+	GENSIA SICOR PHARMS	10MG/ML	N74894 002	APR 19, 2002	APR	NEWA	

DIMYRISTOYL LECITHIN; PERFLEXANE
INJECTABLE; INTRAVENOUS
IMAGENT

>A>	+	ALLIANCE PHARM	0.92MG/VIAL;0.092MG/VIAL	N21191 001	MAY 31, 2002	MAY	NEWA

DIPHENHYDRAMINE HYDROCHLORIDE
INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL

>A>	AP	AM PHARM PARTNERS	50MG/ML	N40466 001	MAY 28, 2002	MAY	NEWA

DONEPEZIL HYDROCHLORIDE
TABLET; ORAL
ARICEPT

>D>		EISAI	5MG	N20690 002	NOV 25, 1996	MAY	CAHN
>D>	+		10MG	N20690 001	NOV 25, 1996	MAY	CAHN
>A>		EISAI MEDCL RES	5MG	N20690 002	NOV 25, 1996	MAY	CAHN
>A>	+		10MG	N20690 001	NOV 25, 1996	MAY	CAHN

DOXEPIN HYDROCHLORIDE
CAPSULE; ORAL
DOXEPIN HCL

>D>	AB	LEDERLE	EQ 10MG BASE	N71685 001	JAN 05, 1988	MAY	DISC
>A>		@	EQ 10MG BASE	N71685 001	JAN 05, 1988	MAY	DISC
>D>	AB		EQ 25MG BASE	N71686 001	JAN 05, 1988	MAY	DISC
>A>		@	EQ 25MG BASE	N71686 001	JAN 05, 1988	MAY	DISC
>D>	AB		EQ 50MG BASE	N71673 001	JAN 05, 1988	MAY	DISC
>A>		@	EQ 50MG BASE	N71673 001	JAN 05, 1988	MAY	DISC
>D>	AB		EQ 75MG BASE	N71674 001	JAN 05, 1988	MAY	DISC
>A>		@	EQ 75MG BASE	N71674 001	JAN 05, 1988	MAY	DISC
>D>	AB		EQ 100MG BASE	N71675 001	JAN 05, 1988	MAY	DISC
>A>		@	EQ 100MG BASE	N71675 001	JAN 05, 1988	MAY	DISC
>D>	AB		EQ 150MG BASE	N71676 001	JAN 05, 1988	MAY	DISC
>A>		@	EQ 150MG BASE	N71676 001	JAN 05, 1988	MAY	DISC

EFAVIRENZ
TABLET; ORAL
SUSTIVA

			BRISTOL MYERS SQUIBB	300MG	N21360	001	FEB 01, 2002	FEB	NEWA
		+		600MG	N21360	002	FEB 01, 2002	FEB	NEWA

ENALAPRIL MALEATE
TABLET; ORAL
VASOTEC

>A>	AB		BIOVAIL	2.5MG	N18998	005	JUL 26, 1988	MAY	CAHN
>A>	AB			5MG	N18998	001	DEC 24, 1985	MAY	CAHN
>A>	AB			10MG	N18998	002	DEC 24, 1985	MAY	CAHN
>A>	AB	+		20MG	N18998	003	DEC 24, 1985	MAY	CAHN
>D>	AB		MERCK	2.5MG	N18998	005	JUL 26, 1988	MAY	CAHN
>D>	AB			5MG	N18998	001	DEC 24, 1985	MAY	CAHN
>D>	AB			10MG	N18998	002	DEC 24, 1985	MAY	CAHN
>D>	AB	+		20MG	N18998	003	DEC 24, 1985	MAY	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
TABLET; ORAL
VASERETIC

>A>	AB		BIOVAIL	5MG;12.5MG	N19221	003	JUL 12, 1995	MAY	CAHN
>A>	AB	+		10MG;25MG	N19221	001	OCT 31, 1986	MAY	CAHN
>D>	AB		MERCK	5MG;12.5MG	N19221	003	JUL 12, 1995	MAY	CAHN
>D>	AB	+		10MG;25MG	N19221	001	OCT 31, 1986	MAY	CAHN

ENALAPRILAT
INJECTABLE; INJECTION
VASOTEC

>A>	AP	+	BIOVAIL	1.25MG/ML	N19309	001	FEB 09, 1988	MAY	CAHN
>D>	AP	+	MERCK	1.25MG/ML	N19309	001	FEB 09, 1988	MAY	CAHN

EPTIFIBATIDE
INJECTABLE; INJECTION
INTEGRILIN

		+	MILLENNIUM PHARMS	2MG/ML	N20718	001	MAY 18, 1998	FEB	CAHN
		+		75MG/100ML	N20718	002	MAY 18, 1998	FEB	CAHN

ERYTHROMYCIN
GEL; TOPICAL
E-GLADES

	AT		GLADES PHARMS	2%	N65009	001	MAR 18, 2002	MAR	NEWA

ESTRADIOL
FILM, EXTENDED RELEASE; TRANSDERMAL
ALORA

>D>	BX		WATSON LABS	0.025MG/24HR	N20655	004	APR 16, 2002	MAY	CMS1
>A>	BX			0.025MG/24HR	N20655	004	APR 05, 2002	MAY	CMS1
	BX			0.025MG/24HR	N20655	004	APR 16, 2002	APR	NEWA

TABLET; ORAL
ESTRADIOL

	AB		USL PHARMA	0.5MG	N40297	001	APR 17, 2002	APR	NEWA

	AB			1MG	N40297 002	APR 17, 2002	APR	NEWA
	AB			2MG	N40297 003	APR 17, 2002	APR	NEWA
		ESTRADIOL; NORGESTIMATE						
		TABLET; ORAL						
		ORTHO-PREFEST						
>D>		+ JOHNSON RW		1MG;1MG;0.09MG	N21040 001	OCT 22, 1999	MAY	CAHN
>A>		+ KING PHARMS		1MG;1MG;0.09MG	N21040 001	OCT 22, 1999	MAY	CAHN
		ETHINYL ESTRADIOL; LEVONORGESTREL						
		TABLET; ORAL-21						
		ALESSE						
>D>	AB	+ WYETH AYERST		0.02MG;0.1MG	N20683 001	MAR 27, 1997	MAY	CTEC
>A>	AB1	+		0.02MG;0.1MG	N20683 001	MAR 27, 1997	MAY	CTEC
	AB	+		0.02MG;0.1MG	N20683 001	MAR 27, 1997	MAR	CTEC
		AVIANE-21						
	AB1	DURAMED PHARM BARR		0.02MG;0.1MG	N75796 002	APR 30, 2001	MAR	CTEC
		LESSINA-21						
	AB2	BARR		0.02MG;0.1MG	N75803 001	MAR 20, 2002	MAR	NEWA
		LEVLITE						
	AB2	+ BERLEX LABS		0.02MG;0.1MG	N20860 001	JUL 13, 1998	MAR	CTEC
>A>		PORTIA-21						
>A>	AB	BARR		0.03MG;0.15MG	N75866 001	MAY 23, 2002	MAY	NEWA
		TABLET; ORAL-28						
		ALESSE						
	AB1	WYETH AYERST		0.02MG;0.1MG	N20683 002	MAR 27, 1997	MAR	CTEC
		AVIANE-28						
	AB1	DURAMED PHARM BARR		0.02MG;0.1MG	N75796 001	APR 30, 2001	MAR	CTEC
		LESSINA-28						
	AB	BARR		0.02MG;0.1MG	N75803 002	MAR 20, 2002	MAR	NEWA
		LEVLITE						
	AB	BERLEX LABS		0.02MG;0.1MG	N20860 002	JUL 13, 1998	MAR	CTEC
>A>		PORTIA-28						
>A>	AB	BARR		0.03MG;0.15MG	N75866 002	MAY 23, 2002	MAY	NEWA
		FAMOTIDINE						
		INJECTABLE; INJECTION						
		FAMOTIDINE						
	AP	BAXTER HLTHCARE		10MG/ML	N75799 001	APR 30, 2002	APR	NEWA
		FAMOTIDINE PRESERVATIVE FREE						
		@ APOTHECON		10MG/ML	N75708 001	APR 16, 2001	MAR	WDAG
	AP	BAXTER HLTHCARE		10MG/ML	N75789 001	APR 30, 2002	APR	NEWA
		FENOFIBRATE						
		CAPSULE; ORAL						
		FENOFIBRATE (MICRONIZED)						
	AB	TEVA		134MG	N75753 002	APR 09, 2002	APR	NEWA
	AB			200MG	N75753 003	APR 09, 2002	APR	NEWA
		TRICOR (MICRONIZED)						
	AB	ABBOTT		134MG	N19304 003	JUN 30, 1999	APR	CFTG
	AB	+		200MG	N19304 004	JUN 30, 1999	APR	CFTG

FLOXURIDINE
INJECTABLE; INJECTION
FUDR

AP	+	FAULDING	500MG/VIAL	N16929 001		APR	CAHN

FLUDROCORTISONE ACETATE
TABLET; ORAL
FLORINEF

AB	+	KING PHARMS	0.1MG	N10060 001		MAR	CFTG

FLUDROCORTISONE ACETATE

AB		IMPAX LABS	0.1MG	N40431 001	MAR 18, 2002	MAR	NEWA

FLUNISOLIDE
SPRAY, METERED; NASAL
FLUNISOLIDE

AB		BAUSCH AND LOMB	0.025MG/SPRAY	N74805 001	FEB 20, 2002	FEB	NEWA

NASALIDE

AB	+	IVAX RES	0.025MG/SPRAY	N18148 001		FEB	CTEC

FLUOCINOLONE ACETONIDE
SOLUTION; TOPICAL
FLUONID

>D>	AT	ALLERGAN HERBERT	0.01%	N87158 001	MAR 17, 1983	MAY	DISC
>A>		@	0.01%	N87158 001	MAR 17, 1983	MAY	DISC

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN
CREAM; TOPICAL
TRI-LUMA

	+	HILL DERMAC	0.01%;4%;0.05%	N21112 001	JAN 18, 2002	JAN	NEWA

FLUOXETINE HYDROCHLORIDE
CAPSULE; ORAL
FLUOXETINE

AB		ALPHAPHARM	EQ 10MG BASE	N75577 001	JAN 29, 2002	JAN	NEWA
AB			EQ 20MG BASE	N75577 002	JAN 29, 2002	JAN	NEWA
AB		BARR	EQ 10MG BASE	N74803 002	JAN 30, 2002	JAN	NEWA
AB		CARLSBAD	EQ 10MG BASE	N76022 001	JAN 30, 2002	JAN	NEWA
AB			EQ 20MG BASE	N76022 002	JAN 30, 2002	JAN	NEWA
AB		DR REDDYS LABS INC	EQ 10MG BASE	N75465 001	JAN 29, 2002	JAN	NEWA
AB			EQ 20MG BASE	N75465 002	JAN 29, 2002	JAN	NEWA
AB		EON	EQ 10MG BASE	N75807 001	JAN 29, 2002	JAN	NEWA
AB			EQ 20MG BASE	N75807 002	JAN 29, 2002	JAN	NEWA
AB		IVAX PHARMS	EQ 10MG BASE	N75245 002	JAN 31, 2002	JAN	NEWA
AB			EQ 20MG BASE	N75245 001	JAN 31, 2002	JAN	NEWA
AB		MALLINCKRODT	EQ 10MG BASE	N75658 001	JAN 29, 2002	JAN	NEWA
AB			EQ 20MG BASE	N75658 002	JAN 29, 2002	JAN	NEWA
AB		MUTUAL PHARMA	EQ 10MG BASE	N75787 001	JAN 29, 2002	JAN	NEWA
AB			EQ 20MG BASE	N75787 002	JAN 29, 2002	JAN	NEWA
AB		MYLAN	EQ 10MG BASE	N75207 001	JAN 30, 2002	JAN	NEWA
AB			EQ 20MG BASE	N75207 002	JAN 30, 2002	JAN	NEWA
AB		RANBAXY	EQ 10MG BASE	N76165 001	FEB 01, 2002	FEB	NEWA
AB			EQ 20MG BASE	N76165 002	FEB 01, 2002	FEB	NEWA

	AB	SIDMAK LABS	EQ 10MG BASE	N76001	001	JAN 29, 2002	JAN	NEWA
	AB		EQ 20MG BASE	N76001	002	JAN 29, 2002	JAN	NEWA
	AB	SIEGFRIED	EQ 10MG BASE	N75464	001	JAN 30, 2002	JAN	NEWA
	AB		EQ 20MG BASE	N75464	002	JAN 30, 2002	JAN	NEWA
	AB	TEVA	EQ 10MG BASE	N75452	001	JAN 29, 2002	JAN	NEWA
	AB		EQ 20MG BASE	N75452	002	JAN 29, 2002	JAN	NEWA
	AB		EQ 40MG BASE	N75452	003	JAN 29, 2002	JAN	NEWA
	AB	WATSON LABS	EQ 10MG BASE	N75662	001	JAN 29, 2002	JAN	NEWA
	AB		EQ 20MG BASE	N75662	002	JAN 29, 2002	JAN	NEWA
		FLUOXETINE HCL						
	AB	GENEVA PHARMS	EQ 20MG BASE	N75049	002	JAN 29, 2002	JAN	NEWA
	AB		EQ 40MG BASE	N75049	003	JAN 29, 2002	JAN	NEWA
		SOLUTION; ORAL						
		FLUOXETINE						
	AA	ALPHARMA	EQ 20MG BASE/5ML	N75690	001	JAN 31, 2002	JAN	NEWA
	AA	MALLINCKRODT	EQ 20MG BASE/5ML	N75920	001	JAN 29, 2002	JAN	NEWA
	AA	NOVEX	EQ 20MG BASE/5ML	N75292	001	FEB 07, 2002	FEB	NEWA
	AA	PHARM ASSOC	EQ 20MG BASE/5ML	N76015	001	JAN 30, 2002	JAN	NEWA
		TABLET; ORAL						
		FLUOXETINE HCL						
	AB	BARR	EQ 10MG BASE	N75810	001	FEB 01, 2002	FEB	NEWA
	AB	DR REDDYS LABS INC	EQ 10MG BASE	N76006	001	JAN 30, 2002	JAN	NEWA
	AB	EON	EQ 10MG BASE	N76024	001	JAN 29, 2002	JAN	NEWA
	AB	TEVA	EQ 10MG BASE	N75872	001	JAN 29, 2002	JAN	NEWA
	AB	ZENITH GOLDLINE	EQ 10MG BASE	N75865	001	FEB 28, 2002	FEB	NEWA
		FLUVOXAMINE MALEATE						
		TABLET; ORAL						
		FLUVOXAMINE MALEATE						
>D>	AB	EON	100MG	N75888	003	NOV 29, 2000	MAY	CRLD
>A>	AB +		100MG	N75888	003	NOV 29, 2000	MAY	CRLD
	AB	MUTUAL PHARM	25MG	N76125	001	APR 29, 2002	APR	NEWA
	AB		50MG	N76125	002	APR 29, 2002	APR	NEWA
	AB		100MG	N76125	003	APR 29, 2002	APR	NEWA
>D>		LUVOX						
>D>	AB	SOLVAY	25MG	N20243	001	DEC 05, 1994	MAY	DISC
>A>		@	25MG	N20243	001	DEC 05, 1994	MAY	DISC
>D>	AB		50MG	N20243	002	DEC 05, 1994	MAY	DISC
>A>		@	50MG	N20243	002	DEC 05, 1994	MAY	DISC
>D>	AB +		100MG	N20243	003	DEC 05, 1994	MAY	DISC
>A>		@	100MG	N20243	003	DEC 05, 1994	MAY	DISC
		FOLIC ACID						
		TABLET; ORAL						
		FOLIC ACID						
	AA +	WATSON LABS	1MG	N80680	001		FEB	CAHN
		FULVESTRANT						
		INJECTABLE; INTRAMUSCULAR						
		FASLODEX						
	+	ASTRAZENECA	50MG/ML	N21344	001	APR 25, 2002	APR	NEWA

GLIPIZIDE
TABLET, EXTENDED RELEASE; ORAL
GLUCOTROL XL

		PFIZER	2.5MG	N20329 003	AUG 10, 1999	FEB	CRLD
			5MG	N20329 001	APR 26, 1994	FEB	CRLD

GRISEOFULVIN, MICROCRYSTALLINE
CAPSULE; ORAL
GRISACTIN

>D>		+ WYETH AYERST	250MG	N50051 001		MAY	DISC
>A>		@	250MG	N50051 001		MAY	DISC

TABLET; ORAL
GRISACTIN

>D>	AB	WYETH AYERST	500MG	N60212 001		MAY	DISC
>A>		@	500MG	N60212 001		MAY	DISC

GRISEOFULVIN, ULTRAMICROCRYSTALLINE
TABLET; ORAL
GRISACTIN ULTRA

>D>	AB	WYETH AYERST	165MG	N62438 001	NOV 17, 1983	MAY	DISC
>A>		@	165MG	N62438 001	NOV 17, 1983	MAY	DISC
>D>	AB		330MG	N62438 002	NOV 17, 1983	MAY	DISC
>A>		@	330MG	N62438 002	NOV 17, 1983	MAY	DISC

GUANFACINE HYDROCHLORIDE
TABLET; ORAL
TENEX

	AB	ESP PHARMA	EQ 1MG BASE	N19032 001	OCT 27, 1986	APR	CAHN
	AB +		EQ 2MG BASE	N19032 002	NOV 07, 1988	APR	CAHN
		@	EQ 3MG BASE	N19032 003	NOV 07, 1988	APR	CAHN

HALOPERIDOL LACTATE
CONCENTRATE; ORAL
HALOPERIDOL

>D>	AA	ALPHARMA	EQ 2MG BASE/ML	N70318 001	APR 11, 1986	MAY	DISC
>A>		@	EQ 2MG BASE/ML	N70318 001	APR 11, 1986	MAY	DISC

HALOTHANE
LIQUID; INHALATION
FLUOTHANE

		@ WYETH AYERST	99.99%	N11338 001		APR	DISC

HALOTHANE

	AN +	ABBOTT	99.99%	N83254 001		APR	CTEC

HYDROCHLOROTHIAZIDE
TABLET; ORAL
ESIDRIX

	AB +	NOVARTIS	100MG	N11793 009		MAR	CRLD

HYDROCHLOROTHIAZIDE

	AB	VINTAGE PHARMS	25MG	N40412 001	MAR 29, 2002	MAR	NEWA
	AB		50MG	N40412 002	MAR 29, 2002	MAR	NEWA

HYDRODIURIL

		@ MERCK	25MG	N11835 003		MAR	DISC

			@	50MG	N11835 006		MAR	DISC
			@	100MG	N11835 007		MAR	DISC
			HYDROCORTISONE					
			TABLET; ORAL					
			CORTEF					
>D>			PHARMACIA AND UPJOHN	5MG	N08697 003		MAY	CRLD
>A>		+		5MG	N08697 003		MAY	CRLD
>D>	BP			10MG	N08697 001		MAY	CRLD
>A>	BP	+		10MG	N08697 001		MAY	CRLD
>D>	BP			20MG	N08697 002		MAY	CRLD
>A>	BP	+		20MG	N08697 002		MAY	CRLD
			HYDROCORTISONE ACETATE					
			CREAM; TOPICAL					
			MICORT-HC					
		+	FERNDALE LABS	2%	N40398 001	MAR 29, 2002	MAR	NEWA
			HYDROCORTISONE BUTYRATE					
			CREAM; TOPICAL					
			LOCOID					
		+	FERNDALE LABS	0.1%	N18514 001	MAR 31, 1982	MAR	CAHN
			LOCOID LIPOCREAM					
		+	FERNDALE LABS	0.1%	N20769 001	SEP 08, 1997	MAR	CAHN
			OINTMENT; TOPICAL					
			LOCOID					
		+	FERNDALE LABS	0.1%	N18652 001	OCT 29, 1982	MAR	CAHN
			HYDROXYZINE HYDROCHLORIDE					
			SYRUP; ORAL					
			HYDROXYZINE HCL					
	AA		VINTAGE PHARMS	10MG/5ML	N40391 001	APR 10, 2002	APR	NEWA
			IDARUBICIN HYDROCHLORIDE					
			INJECTABLE; INJECTION					
			IDAMYCIN					
>D>		+	PHARMACIA AND UPJOHN	5MG/VIAL	N50661 002	SEP 27, 1990	MAY	CFTG
>A>	AP	+		5MG/VIAL	N50661 002	SEP 27, 1990	MAY	CFTG
>D>		+		10MG/VIAL	N50661 001	SEP 27, 1990	MAY	CFTG
>A>	AP	+		10MG/VIAL	N50661 001	SEP 27, 1990	MAY	CFTG
>D>		+		20MG/VIAL	N50661 003	APR 25, 1995	MAY	CFTG
>A>	AP	+		20MG/VIAL	N50661 003	APR 25, 1995	MAY	CFTG
			IDAMYCIN PFS					
>D>		+	PHARMACIA AND UPJOHN	1MG/ML	N50734 001	FEB 17, 1997	MAY	CFTG
>A>	AP	+		1MG/ML	N50734 001	FEB 17, 1997	MAY	CFTG
>A>			IDARUBICIN HCL					
>A>	AP		GENSIA SICOR PHARMS	5MG/VIAL	N65037 003	MAY 01, 2002	MAY	NEWA
>A>	AP			10MG/VIAL	N65037 002	MAY 01, 2002	MAY	NEWA
>A>	AP			20MG/VIAL	N65037 001	MAY 01, 2002	MAY	NEWA
>A>			IDARUBICIN HCL PFS					
>A>	AP		GENSIA SICOR PHARMS	1MG/ML	N65036 001	MAY 01, 2002	MAY	NEWA

>A>		IFOSFAMIDE						
>A>		INJECTABLE; INJECTION						
>A>		IFSOFAMIDE						
>A>		AM PHARM PARTNERS	1GM/VIAL	N76078 001	MAY 28, 2002	MAY	NEWA	
>A>	+		3GM/VIAL	N76078 002	MAY 28, 2002	MAY	NEWA	
		IFOSFAMIDE; MESNA						
		INJECTABLE; INTRAVENOUS						
		IFOSFAMIDE/MESNA KIT						
	+	GENSIA SICOR PHARMS	1GM /20ML(50MG/ML);1GM /10ML(100MG/ML)	N75874 001	FEB 26, 2002	FEB	NEWA	
	+		3GM /60ML(50MG/ML);1GM /10ML(100MG/ML)	N75874 002	FEB 26, 2002	FEB	NEWA	
		INDOMETHACIN						
		CAPSULE, EXTENDED RELEASE; ORAL						
		INDOMETHACIN						
	AB	ABLE	75MG	N76114 001	FEB 06, 2002	FEB	NEWA	
		SUPPOSITORY; RECTAL						
>D>		INDOCIN						
>D>	AB +	MERCK	50MG	N17814 001	AUG 13, 1984	MAY	DISC	
>A>		@	50MG	N17814 001	AUG 13, 1984	MAY	DISC	
		INDOMETHEGAN						
>D>	AB	G AND W LABS	50MG	N73314 001	AUG 31, 1992	MAY	CRLD	
>A>	+		50MG	N73314 001	AUG 31, 1992	MAY	CRLD	
		KETOCONAZOLE						
		TABLET; ORAL						
		KETOCONAZOLE						
	AB	TORPHARM	200MG	N75912 001	JAN 10, 2002	JAN	NEWA	
		KETOPROFEN						
		CAPSULE, EXTENDED RELEASE; ORAL						
		KETOPROFEN						
	AB	MYLAN	100MG	N75679 003	FEB 20, 2002	FEB	NEWA	
	AB		150MG	N75679 002	FEB 20, 2002	FEB	NEWA	
	AB		200MG	N75679 001	FEB 20, 2002	FEB	NEWA	
		KETOROLAC TROMETHAMINE						
		INJECTABLE; INJECTION						
		KETOROLAC TROMETHAMINE						
	AP	AM PHARM PARTNERS	15MG/ML	N75784 001	JAN 11, 2002	JAN	NEWA	
	AP		30MG/ML	N75784 002	JAN 11, 2002	JAN	NEWA	
		LACTULOSE						
		SOLUTION; ORAL						
		LACTULOSE						
	AA	NOVEX	10GM/15ML	N75911 001	FEB 21, 2002	FEB	NEWA	

		LAMOTRIGINE						
		TABLET, CHEWABLE; ORAL						
		LAMICTAL CD						
		+ GLAXOSMITHKLINE	25MG	N20764	002	AUG 24, 1998	MAR	CRLD
		@	100MG	N20764	003	AUG 24, 1998	MAR	DISC
		LEUPROLIDE ACETATE						
		INJECTABLE; SUBCUTANEOUS						
		ELIGARD						
		+ ATRIX	7.5MG/VIAL	N21343	001	JAN 23, 2002	JAN	NEWA
		LEVOTHYROXINE SODIUM						
		TABLET; ORAL						
		LEVO-T						
	BX	MOVA	0.025MG	N21342	001	MAR 01, 2002	MAR	NEWA
	BX		0.05MG	N21342	002	MAR 01, 2002	MAR	NEWA
	BX		0.075MG	N21342	003	MAR 01, 2002	MAR	NEWA
	BX		0.088MG	N21342	004	MAR 01, 2002	MAR	NEWA
	BX		0.1MG	N21342	005	MAR 01, 2002	MAR	NEWA
	BX		0.112MG	N21342	006	MAR 01, 2002	MAR	NEWA
	BX		0.125MG	N21342	007	MAR 01, 2002	MAR	NEWA
	BX		0.15MG	N21342	008	MAR 01, 2002	MAR	NEWA
	BX		0.175MG	N21342	009	MAR 01, 2002	MAR	NEWA
	BX		0.2MG	N21342	010	MAR 01, 2002	MAR	NEWA
	BX +		0.3MG	N21342	011	MAR 01, 2002	MAR	NEWA
>A>		NOVOTHYROX						
>A>	BX	GENPHARM	0.025MG	N21292	001	MAY 31, 2002	MAY	NEWA
>A>	BX		0.05MG	N21292	002	MAY 31, 2002	MAY	NEWA
>A>	BX		0.075MG	N21292	003	MAY 31, 2002	MAY	NEWA
>A>	BX		0.088MG	N21292	004	MAY 31, 2002	MAY	NEWA
>A>	BX		0.1MG	N21292	005	MAY 31, 2002	MAY	NEWA
>A>	BX		0.112MG	N21292	006	MAY 31, 2002	MAY	NEWA
>A>	BX		0.125MG	N21292	007	MAY 31, 2002	MAY	NEWA
>A>	BX		0.137MG	N21292	008	MAY 31, 2002	MAY	NEWA
>A>	BX		0.15MG	N21292	009	MAY 31, 2002	MAY	NEWA
>A>	BX		0.175MG	N21292	010	MAY 31, 2002	MAY	NEWA
>A>	BX		0.2MG	N21292	011	MAY 31, 2002	MAY	NEWA
>A>	BX +		0.3MG	N21292	012	MAY 31, 2002	MAY	NEWA
		MAZINDOL						
		TABLET; ORAL						
		MAZANOR						
		@ WYETH AYERST	1MG	N17980	002		APR	DISC
		SANOREX						
		NOVARTIS	1MG	N17247	001		APR	CTEC
		MEFLOQUINE HYDROCHLORIDE						
		TABLET; ORAL						
		LARIAM						
	AB +	ROCHE	250MG	N19591	001	MAY 02, 1989	FEB	CFTG
		MEFLOQUINE HCL						
	AB	GENEVA PHARMS TECH	250MG	N76175	001	FEB 20, 2002	FEB	NEWA

		MEGESTROL ACETATE					
		SUSPENSION; ORAL					
		MEGESTROL ACETATE					
	AB	ROXANE	40MG/ML	N75997 001	FEB 15, 2002	FEB	NEWA
		MEQUINOL; TRETINOIN					
		SOLUTION; TOPICAL					
		SOLAGE					
	+	GALDERMA LABS	2%;0.01%	N20922 001	DEC 10, 1999	APR	CAHN
		MESNA					
		INJECTABLE; INTRAVENOUS					
		MESNEX					
	AP +	BAXTER HLTHCARE	100MG/ML	N19884 001	DEC 30, 1988	MAR	CAHN
		TABLET; ORAL					
	+	BRISTOL MYERS SQUIBB	400MG	N20855 001	MAR 21, 2002	MAR	NEWA
		MESTRANOL; NORETHINDRONE					
		TABLET; ORAL-28					
		NORINYL 1+50 28-DAY					
	AB	WATSON LABS	0.05MG;1MG	N16659 001		JAN	CAHN
		METAPROTERENOL SULFATE					
		SOLUTION; INHALATION					
		METAPROTERENOL SULFATE					
>A>	AN	MORTON GROVE	0.4%	N75586 001	MAY 30, 2002	MAY	NEWA
>A>	AN		0.6%	N75586 002	MAY 30, 2002	MAY	NEWA
		METFORMIN HYDROCHLORIDE					
		TABLET; ORAL					
		GLUCOPHAGE					
	AB	BRISTOL MYERS SQUIBB	500MG	N20357 001	MAR 03, 1995	JAN	CFTG
	AB		850MG	N20357 002	MAR 03, 1995	JAN	CFTG
	AB +		1GM	N20357 005	NOV 05, 1998	JAN	CFTG
		METFORMIN HCL					
	AB	ALPHAPHARM	500MG	N75969 001	JAN 29, 2002	JAN	NEWA
	AB		850MG	N75969 002	JAN 29, 2002	JAN	NEWA
	AB		1GM	N75969 003	JAN 29, 2002	JAN	NEWA
	AB	ANDRX PHARMS	500MG	N75961 001	JAN 25, 2002	JAN	NEWA
	AB		850MG	N75961 002	JAN 25, 2002	JAN	NEWA
	AB		1GM	N75961 003	JAN 25, 2002	JAN	NEWA
	AB	BARR	500MG	N75971 001	JAN 25, 2002	JAN	NEWA
	AB		850MG	N75971 002	JAN 25, 2002	JAN	NEWA
	AB		1GM	N75971 003	JAN 25, 2002	JAN	NEWA
	AB	CARACO	500MG	N75967 001	JAN 29, 2002	JAN	NEWA
	AB		850MG	N75967 002	JAN 29, 2002	JAN	NEWA
	AB		1GM	N75967 003	JAN 29, 2002	JAN	NEWA
	AB	EON	500MG	N75965 001	JAN 25, 2002	JAN	NEWA
	AB		850MG	N75965 002	JAN 25, 2002	JAN	NEWA
	AB		1GM	N75965 003	JAN 25, 2002	JAN	NEWA
>A>	AB	GENEVA PHARMS	500MG	N75985 001	JAN 25, 2002	MAY	CAHN
>A>	AB		850MG	N75985 002	JAN 25, 2002	MAY	CAHN

>A>	AB		1GM	N75985	003	JAN 25, 2002	MAY	CAHN
>D>	AB	GENEVA PHARMS TECH	500MG	N75985	001	JAN 25, 2002	MAY	CAHN
	AB		500MG	N75985	001	JAN 25, 2002	JAN	NEWA
>D>	AB		850MG	N75985	002	JAN 25, 2002	MAY	CAHN
	AB		850MG	N75985	002	JAN 25, 2002	JAN	NEWA
>D>	AB		1GM	N75985	003	JAN 25, 2002	MAY	CAHN
	AB		1GM	N75985	003	JAN 25, 2002	JAN	NEWA
	AB	GENPHARM	500MG	N75973	001	JAN 25, 2002	JAN	NEWA
	AB		850MG	N75973	002	JAN 25, 2002	JAN	NEWA
	AB		1GM	N75973	003	JAN 25, 2002	JAN	NEWA
	AB	GOLDLINE	500MG	N75972	001	JAN 24, 2002	JAN	NEWA
	AB		625MG	N75972	005	JAN 24, 2002	JAN	NEWA
	AB		750MG	N75972	004	JAN 24, 2002	JAN	NEWA
	AB		850MG	N75972	002	JAN 24, 2002	JAN	NEWA
	AB		1GM	N75972	003	JAN 24, 2002	JAN	NEWA
	AB	MUTUAL PHARMA	500MG	N76038	001	FEB 21, 2002	FEB	NEWA
	AB		850MG	N76038	002	FEB 21, 2002	FEB	NEWA
	AB		1GM	N76038	003	FEB 21, 2002	FEB	NEWA
	AB	MYLAN	500MG	N75976	001	JAN 24, 2002	JAN	NEWA
	AB		850MG	N75976	002	JAN 24, 2002	JAN	NEWA
	AB		1GM	N75976	003	JAN 24, 2002	JAN	NEWA
	AB	PUREPAC PHARM	500MG	N76033	001	JAN 24, 2002	JAN	NEWA
	AB		850MG	N76033	002	JAN 24, 2002	JAN	NEWA
	AB		1GM	N76033	003	JAN 24, 2001	JAN	NEWA
	AB	TEVA	500MG	N75978	001	JAN 25, 2002	JAN	NEWA
	AB		850MG	N75978	002	JAN 25, 2002	JAN	NEWA
	AB	TORPHARM	500MG	N75984	001	APR 23, 2002	APR	NEWA
	AB		850MG	N75984	002	APR 23, 2002	APR	NEWA
	AB		1GM	N75984	003	APR 23, 2002	APR	NEWA
	AB	WATSON LABS	500MG	N75979	001	JAN 24, 2002	JAN	NEWA
	AB		850MG	N75979	002	JAN 24, 2002	JAN	NEWA
	AB		1GM	N75979	003	JAN 24, 2002	JAN	NEWA
	AB	ZENITH GOLDLINE	500MG	N75975	001	JAN 24, 2002	JAN	NEWA
	AB		625MG	N75975	004	JAN 24, 2002	JAN	NEWA
	AB		750MG	N75975	005	JAN 24, 2002	JAN	NEWA
	AB		850MG	N75975	002	JAN 24, 2002	JAN	NEWA
	AB		1GM	N75975	003	JAN 24, 2002	JAN	NEWA

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

+		KING PHARMS	500MG/VIAL	N11559	001		FEB	CAHN
+			2.5GM/VIAL	N11559	002		FEB	CAHN
+			5GM/VIAL	N11559	003		FEB	CAHN

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HCL

AB		PUREPAC PHARM	5MG	N40321	001	FEB 05, 2002	FEB	NEWA
AB			10MG	N40321	002	FEB 05, 2002	FEB	NEWA
AB			20MG	N40321	003	FEB 05, 2002	FEB	NEWA

		METHYLPREDNISOLONE						
		TABLET; ORAL						
		METHYLPREDNISOLONE						
>A>	AB	GENEVA PHARMS	4MG	N40194 001	OCT 31, 1997	MAY	CAHN	
>D>	AB	GENEVA PHARMS TECH	4MG	N40194 001	OCT 31, 1997	MAY	CAHN	
		MIDAZOLAM HYDROCHLORIDE						
		SYRUP; ORAL						
		MIDAZOLAM HCL						
	AA	RANBAXY	EQ 2MG BASE/ML	N76058 001	MAR 15, 2002	MAR	NEWA	
	AA	ROXANE	EQ 2MG BASE/ML	N75873 001	APR 30, 2002	APR	NEWA	
		VERSED						
	AA +	ROCHE	EQ 2MG BASE/ML	N20942 001	OCT 15, 1998	MAR	CFTG	
		MILRINONE LACTATE						
		INJECTABLE; INJECTION						
>A>		MILRINONE LACTATE						
>A>	AP	ABBOTT	EQ 1MG BASE/ML	N75884 001	MAY 28, 2002	MAY	NEWA	
>A>	AP	AM PHARM PARTNERS	EQ 1MG BASE/ML	N75936 001	MAY 28, 2002	MAY	NEWA	
>A>	AP	BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	N75852 001	MAY 28, 2002	MAY	NEWA	
>A>	AP	BEDFORD	EQ 1MG BASE/ML	N75660 001	MAY 28, 2002	MAY	NEWA	
>A>	AP		EQ 20MG /20ML (1MG/ML)	N75660 002	MAY 28, 2002	MAY	NEWA	
>A>	AP		EQ 50MG /50ML (1MG/ML)	N75660 003	MAY 28, 2002	MAY	NEWA	
>A>	AP	ESI LEDERLE	EQ 1MG BASE/ML	N75530 001	MAY 28, 2002	MAY	NEWA	
>A>	AP	FAULDING	EQ 1MG BASE/ML	N75830 001	MAY 28, 2002	MAY	NEWA	
>A>		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
>A>	AP	ABBOTT	EQ 20MG BASE/100ML	N75885 001	MAY 28, 2002	MAY	NEWA	
>A>	AP +		EQ 40MG BASE/200ML	N75885 002	MAY 28, 2002	MAY	NEWA	
>A>	AP	BAXTER HLTHCARE	EQ 20MG BASE/100ML	N75834 001	MAY 28, 2002	MAY	NEWA	
>A>	AP		EQ 40MG BASE/100ML	N75834 002	MAY 28, 2002	MAY	NEWA	
>A>	AP	ESI LEDERLE	EQ 20MG BASE/100ML	N75510 001	MAY 28, 2002	MAY	NEWA	
		PRIMACOR						
>D>	+	SANOFI SYNTHELABO	EQ 1MG BASE/ML	N19436 001	DEC 31, 1987	MAY	CFTG	
>A>	AP +		EQ 1MG BASE/ML	N19436 001	DEC 31, 1987	MAY	CFTG	
		PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	+	SANOFI SYNTHELABO	EQ 20MG BASE/100ML	N20343 003	AUG 09, 1994	MAY	CFTG	
>A>	AP		EQ 20MG BASE/100ML	N20343 003	AUG 09, 1994	MAY	CFTG	
>A>	AP +		EQ 40MG BASE/100ML	N20343 004	AUG 09, 1994	MAY	CFTG	
>D>			EQ 40MG BASE/100ML	N20343 004	AUG 09, 1994	MAY	CFTG	
		MOMETASONE FUROATE						
		OINTMENT; TOPICAL						
		ELOCON						
	AB +	SCHERING	0.1%	N19543 001	APR 30, 1987	MAR	CFTG	
		MOMETASONE FUROATE						
	AB	CLAY PARK	0.1%	N76067 001	MAR 18, 2002	MAR	NEWA	
		MORPHINE SULFATE						
		CAPSULE, EXTENDED RELEASE; ORAL						
		AVINZA						
		ELAN PHARM	30MG	N21260 001	MAR 20, 2002	MAR	NEWA	
			60MG	N21260 002	MAR 20, 2002	MAR	NEWA	

				90MG	N21260 003	MAR 20, 2002	MAR	NEWA
		+		120MG	N21260 004	MAR 20, 2002	MAR	NEWA
			NABUMETONE					
			TABLET; ORAL					
			NABUMETONE					
	AB		EON	500MG	N75280 001	FEB 25, 2002	FEB	NEWA
	AB			750MG	N75280 002	FEB 25, 2002	FEB	NEWA
	AB		INVAMED	500MG	N75590 001	FEB 25, 2002	FEB	NEWA
	AB			750MG	N75590 002	FEB 25, 2002	FEB	NEWA
			NALTREXONE HYDROCHLORIDE					
			TABLET; ORAL					
			NALTREXONE HCL					
			MALLINCKRODT	25MG	N76264 001	MAR 22, 2002	MAR	NEWA
	AB			50MG	N76264 002	MAR 22, 2002	MAR	NEWA
		+		100MG	N76264 003	MAR 22, 2002	MAR	NEWA
			NEOMYCIN SULFATE					
			SOLUTION; ORAL					
			MYCIFRADIN					
>D>		+	PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N50285 001		MAY	CFTG
>A>	AA	+		EQ 87.5MG BASE/5ML	N50285 001		MAY	CFTG
>A>			NEO-FRADIN					
>A>	AA		PHARMATEK	EQ 87.5MG BASE/5ML	N65010 001	MAY 23, 2002	MAY	NEWA
			NISOLDIPINE					
			TABLET, EXTENDED RELEASE; ORAL					
			SULAR					
		+	FIRST HORIZON	10MG	N20356 001	FEB 02, 1995	MAR	CAHN
				20MG	N20356 002	FEB 02, 1995	MAR	CAHN
		+		30MG	N20356 003	FEB 02, 1995	MAR	CAHN
		+		40MG	N20356 004	FEB 02, 1995	MAR	CAHN
		+	WHITEHALL ROBINS	10MG	N20356 001	FEB 02, 1995	FEB	CAHN
				20MG	N20356 002	FEB 02, 1995	FEB	CAHN
		+		40MG	N20356 004	FEB 02, 1995	FEB	CAHN
			NITISINONE					
			CAPSULE; ORAL					
			ORFADIN					
>D>			R R REGISTRATIONS	2MG	N21232 001	JAN 18, 2002	MAY	CAHN
				2MG	N21232 001	JAN 18, 2002	JAN	NEWA
>D>				5MG	N21232 002	JAN 18, 2002	MAY	CAHN
				5MG	N21232 002	JAN 18, 2002	JAN	NEWA
>D>		+		10MG	N21232 003	JAN 18, 2002	MAY	CAHN
		+		10MG	N21232 003	JAN 18, 2002	JAN	NEWA
>A>			SWEDISH ORPHAN	2MG	N21232 001	JAN 18, 2002	MAY	CAHN
>A>				5MG	N21232 002	JAN 18, 2002	MAY	CAHN
>A>		+		10MG	N21232 003	JAN 18, 2002	MAY	CAHN

NITROFURANTOIN
SUSPENSION; ORAL
FURADANTIN
\+ FIRST HORIZON 25MG/5ML N09175 001 JAN CAHN

NITROGLYCERIN
AEROSOL; SUBLINGUAL
NITROLINGUAL
@ FIRST HORIZON 0.4MG/SPRAY N18705 001 OCT 31, 1985 APR CAHN
SPRAY, METERED; SUBLINGUAL
NITROLINGUAL PUMPSPRAY
\+ FIRST HORIZON 0.4MG/SPRAY N18705 002 JAN 10, 1997 APR CAHN

NORETHINDRONE
TABLET; ORAL
NOR-QD
>D> + WATSON LABS 0.35MG N17060 001 MAY CAHN
>A> + WATSON LABS (UTAH) 0.35MG N17060 001 MAY CAHN

OFLOXACIN
INJECTABLE; INJECTION
FLOXIN
AP + JOHNSON RW 40MG/ML N20087 003 MAR 31, 1992 JAN CFTG
OFLOXACIN
AP BEDFORD 40MG/ML N75762 001 JAN 16, 2002 JAN NEWA

OLMESARTAN MEDOXOMIL
TABLET; ORAL
BENICAR
SANKYO 5MG N21286 001 APR 25, 2002 APR NEWA
20MG N21286 003 APR 25, 2002 APR NEWA
\+ 40MG N21286 004 APR 25, 2002 APR NEWA

OXAPROZIN
TABLET; ORAL
OXAPROZIN
AB CARACO 600MG N75844 001 JAN 03, 2002 JAN NEWA
>A> AB IVAX PHARMS 600MG N75846 001 MAY 13, 2002 MAY NEWA

PACLITAXEL
INJECTABLE; INJECTION
PACLITAXEL
>A> AP ABBOTT 6MG/ML N76131 001 MAY 08, 2002 MAY NEWA

PAMIDRONATE DISODIUM
INJECTABLE; INJECTION
>A> PAMIDRONATE DISODIUM
>A> AP AESGEN 30MG/VIAL N75594 001 MAY 06, 2002 MAY NEWA
>A> AP 90MG/VIAL N75594 002 MAY 06, 2002 MAY NEWA
>A> AP AM PHARM PARTNERS 30MG/VIAL N75773 001 MAY 06, 2002 MAY NEWA
>A> AP 30MG /10ML(3MG/ML) N76207 001 MAY 17, 2002 MAY NEWA
>A> AP 90MG/VIAL N75773 002 MAY 06, 2002 MAY NEWA

>A>	AP		90MG /10ML(9MG/ML)	N76207 002	MAY 17, 2002	MAY	NEWA	
>A>	AP	BEDFORD	30MG /10ML(3MG/ML)	N21113 001	MAR 04, 2002	MAY	CDFR	
>A>	AP +		90MG /10ML(9MG/ML)	N21113 002	MAR 04, 2002	MAY	CDFR	
>A>	AP	GENSIA SICOR PHARMS	30MG /10ML(3MG/ML)	N76153 001	MAR 27, 2002	MAY	CDFR	
>A>	AP		90MG /10ML(9MG/ML)	N76153 002	MAR 27, 2002	MAY	CDFR	
>D>	INJECTABLE; IV (INFUSION)							
>D>	AP	BEDFORD	30MG /10ML(3MG/ML)	N21113 001	MAR 04, 2002	MAR	NEWA	
>D>	AP +		90MG /10ML(9MG/ML)	N21113 002	MAR 04, 2002	MAR	NEWA	
>D>	AP	GENSIA SICOR PHARMS	30MG /10ML(3MG/ML)	N76153 001	MAR 27, 2002	MAR	NEWA	
>D>	AP		90MG /10ML(9MG/ML)	N76153 002	MAR 27, 2002	MAR	NEWA	
	PENICILLIN V POTASSIUM							
	FOR SOLUTION; ORAL							
	PEN-VEE K							
>D>	AA	WYETH AYERST	EQ 125MG BASE/5ML	N60007 001		MAY	DISC	
>A>	@		EQ 125MG BASE/5ML	N60007 001		MAY	DISC	
>D>	AA		EQ 250MG BASE/5ML	N60007 002		MAY	DISC	
>A>	@		EQ 250MG BASE/5ML	N60007 002		MAY	DISC	
	PENTAGASTRIN							
	INJECTABLE; INJECTION							
	PEPTAVLON							
	@ WYETH AYERST		0.25MG/ML	N17048 001		APR	DISC	
	PHENDIMETRAZINE TARTRATE							
	TABLET; ORAL							
	PHENDIMETRAZINE TARTRATE							
AA	MIKART		35MG	N89452 001	OCT 30, 1991	MAR	CMFD	
	PHENTERMINE HYDROCHLORIDE							
	CAPSULE; ORAL							
	PHENTERMINE HCL							
AA	VINTAGE PHARMS		37.5MG	N40377 001	JAN 04, 2002	JAN	NEWA	
	PHENYTOIN							
	SUSPENSION; ORAL							
	PHENTYTOIN							
AB	MORTON GROVE		125MG/5ML	N40420 001	APR 19, 2002	APR	NEWA	
	PODOFILOX							>D>
	SOLUTION; TOPICAL							>A>
	CONDYLOX							
AT +	PADDOCK		0.5%	N19795 001	DEC 13, 1990	JAN	CFTG	>D>
	PODOFILOX							>A>
AT	PADDOCK		0.5%	N75600 001	JAN 29, 2002	JAN	NEWA	>D>
								>A>
								>D>
								>A>
								>D>
								>A>
								>D>
								>A>

POTASSIUM CHLORIDE
TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

AB	ANDRX PHARMS	10MEQ	N75604 001	APR 10, 2002	APR	NEWA
AB		20MEQ	N75604 002	APR 10, 2002	APR	NEWA
AB	KV PHARM	20MEQ	N76044 001	APR 05, 2002	APR	NEWA

PRAVASTATIN SODIUM
TABLET; INJECTION
PRAVACHOL

+	BRISTOL MYERS SQUIBB	80MG	N19898 008	DEC 18, 2001	MAR	NEWA

TABLET; ORAL

	BRISTOL MYERS SQUIBB	40MG	N19898 004	MAR 22, 1993	MAR	CRLD
+		80MG	N19898 008	DEC 18, 2001	APR	CDFR

PREDNISOLONE
SYRUP; ORAL
PREDNISOLONE

AA	KV PHARM	15MG/5ML	N40364 001	APR 10, 2002	APR	NEWA

PROMETHAZINE HYDROCHLORIDE
SUPPOSITORY; RECTAL
PHENERGAN

AB	+ WYETH AYERST	25MG	N10926 001		FEB	CTEC

PROMETHAZINE HCL

AB	G AND W LABS	25MG	N40428 001	FEB 05, 2002	FEB	NEWA

PROPAFENONE HYDROCHLORIDE
TABLET; ORAL
PROPAFENONE HCL

AB	KV PHARM	150MG	N76193 001	FEB 07, 2002	FEB	NEWA
AB		225MG	N76193 002	FEB 07, 2002	FEB	NEWA
AB		300MG	N76193 003	FEB 07, 2002	FEB	NEWA

PROPRANOLOL HYDROCHLORIDE
TABLET; ORAL
PROPRANOLOL HCL

	@ LEDERLE	60MG	N71495 001	DEC 31, 1987	FEB	DISC
>D> AB		80MG	N70128 001	JUL 30, 1985	MAY	CAHN
>A>	@	80MG	N70128 001	JUL 30, 1985	MAY	CAHN
	@	90MG	N71496 001	DEC 31, 1987	FEB	DISC
>D> AB	PUREPAC PHARM	10MG	N70814 001	NOV 03, 1986	MAY	DISC
>A>	@	10MG	N70814 001	NOV 03, 1986	MAY	DISC
>D> AB		20MG	N70815 001	NOV 03, 1986	MAY	DISC
>A>	@	20MG	N70815 001	NOV 03, 1986	MAY	DISC
>D> AB		40MG	N70816 001	NOV 03, 1986	MAY	DISC
>A>	@	40MG	N70816 001	NOV 03, 1986	MAY	DISC
>D> AB		60MG	N70817 001	NOV 03, 1986	MAY	DISC
>A>	@	60MG	N70817 001	NOV 03, 1986	MAY	DISC
>D> AB		80MG	N70757 001	NOV 03, 1986	MAY	DISC
>A>	@	80MG	N70757 001	NOV 03, 1986	MAY	DISC

QUINETHAZONE
TABLET; ORAL
HYDROMOX
@ LEDERLE 50MG N13264 001 APR DISC

RABEPRAZOLE SODIUM
TABLET, DELAYED RELEASE; ORAL
ACIPHEX
>D> + EISAI 20MG N20973 002 AUG 19, 1999 MAY CAHN
>A> + EISAI MEDCL RES 20MG N20973 002 AUG 19, 1999 MAY CAHN

SECRETIN
FOR SOLUTION; INTRAVENOUS
SECREFLO
+ CHIRHOCLIN 16UGM/VIAL N21209 001 APR 04, 2002 APR NEWA

SELEGILINE HYDROCHLORIDE
TABLET; ORAL
SELEGILINE HCL
AB CLONMEL HLTHCARE 5MG N74641 001 AUG 02, 1996 APR CAHN

SULFAMETHOXAZOLE
TABLET; ORAL
GANTANOL
>D> + @ ROCHE 500MG N12715 002 MAY CTEC
>A> @ 500MG N12715 002 MAY CTEC

SULFAMETHOXAZOLE; TRIMETHOPRIM
SUSPENSION; ORAL
BACTRIM PEDIATRIC
@ WOMEN FIRST HLTHCARE 200MG/5ML;40MG/5ML N17560 002 APR DISC
SEPTRA
AB + MONARCH PHARMS 200MG/5ML;40MG/5ML N17598 001 APR CRLD

SULFASALAZINE
TABLET; ORAL
SULFASALAZINE
AB VINTAGE PHARMS 500MG N40349 001 JAN 11, 2002 JAN NEWA
TABLET, DELAYED RELEASE; ORAL
AZULFIDINE EN-TABS
AB + PHARMACIA AND UPJOHN 500MG N07073 002 APR 06, 1983 JAN CFTG
SULFASALAZINE
AB VINTAGE PHARMS 500MG N75339 001 JAN 11, 2002 JAN NEWA

TERBUTALINE SULFATE
INJECTABLE; INJECTION
BRETHINE
+ NEOSAN PHARMS 1MG/ML N18571 001 FEB CAHN
TABLET; ORAL
AB NEOSAN PHARMS 2.5MG N17849 001 FEB CAHN
AB + 5MG N17849 002 FEB CAHN

	TESTOSTERONE						
	FILM, EXTENDED RELEASE; TRANSDERMAL						
	TESTODERM TTS						
BX	+ ALZA	5MG/24HR	N20791	001	DEC 18, 1997	JAN	CTNA
	TETRACYCLINE HYDROCHLORIDE						
	FIBER, EXTENDED RELEASE; PERIODONTAL						
	ACTISITE						
	+ ALZA	12.7MG/FIBER	N50653	001	MAR 25, 1994	FEB	CAHN
	SUSPENSION; ORAL						
	ACHROMYCIN V						
	@ LEDERLE	125MG/5ML	N50263	002		APR	DISC
	SUMYCIN						
	+ APOTHECON	125MG/5ML	N60400	001		APR	CTEC
	TABLET; ORAL						
>D>	@ APOTHECON	50MG	N61147	003		MAY	CAHN
>D>	@	100MG	N61147	002		MAY	CAHN
>D>		250MG	N61147	001		MAY	CAHN
>D>	+	500MG	N61147	004		MAY	CAHN
>A>	@ PAR PHARM	50MG	N61147	003		MAY	CAHN
>A>	@	100MG	N61147	002		MAY	CAHN
>A>		250MG	N61147	001		MAY	CAHN
>A>	+	500MG	N61147	004		MAY	CAHN
	THIOTEPA						
	INJECTABLE; INJECTION						
	THIOTEPA						
AP	AM PHARM PARTNERS	15MG/VIAL	N75698	001	SEP 20, 2001	FEB	CAHN
	THIOTHIXENE HYDROCHLORIDE						
	CONCENTRATE; ORAL						
	THIOTHIXENE HCL INTENSOL						
	@ ROXANE	EQ 5MG BASE/ML	N73494	001	JUN 30, 1992	JAN	DISC
	TINZAPARIN SODIUM						
	INJECTABLE; INJECTION						
	INNOHEP						
	+ LEO PHARM	20,000 IU/ML	N20484	001	JUL 14, 2000	APR	CAHN
	TOBRAMYCIN						
	SOLUTION/DROPS; OPHTHALMIC						
	TOBRAMYCIN						
AT	NOVEX	0.3%	N65087	001	FEB 25, 2002	FEB	NEWA
	TOBRAMYCIN SULFATE						
	INJECTABLE; INJECTION						
	TOBRAMYCIN SULFATE						
	@ ASTRAZENECA	EQ 40MG BASE/ML	N63120	001	OCT 31, 1994	FEB	DISC
	@	EQ 40MG BASE/ML	N63122	001	OCT 31, 1994	JAN	DISC

		TOPIRAMATE						
		TABLET; ORAL						
		TOPAMAX						
		+ JOHNSON AND JOHNSON	25MG	N20505 004	DEC 24, 1996	JAN	CAHN
		@	50MG	N20505 005	DEC 24, 1996	JAN	CAHN
			100MG	N20505 001	DEC 24, 1996	JAN	CAHN
			200MG	N20505 002	DEC 24, 1996	JAN	CAHN
		@	300MG	N20505 003	DEC 24, 1996	JAN	CAHN
		@	400MG	N20505 006	DEC 24, 1996	JAN	CAHN
		TORSEMIDE						
		TABLET; ORAL						
		DEMADEX						
>D>		ROCHE	5MG	N20136 001	AUG 23, 1993	MAY	CFTG
>A>	AB		5MG	N20136 001	AUG 23, 1993	MAY	CFTG
>D>			10MG	N20136 002	AUG 23, 1993	MAY	CFTG
>A>	AB		10MG	N20136 002	AUG 23, 1993	MAY	CFTG
>D>		+	20MG	N20136 003	AUG 23, 1993	MAY	CFTG
>A>	AB	+	20MG	N20136 003	AUG 23, 1993	MAY	CFTG
>D>			100MG	N20136 004	AUG 23, 1993	MAY	CFTG
>A>	AB		100MG	N20136 004	AUG 23, 1993	MAY	CFTG
>A>		TORSEMIDE						
>A>	AB	TEVA	5MG	N76110 001	MAY 14, 2002	MAY	NEWA
>A>	AB		10MG	N76110 002	MAY 14, 2002	MAY	NEWA
>A>	AB		20MG	N76110 003	MAY 14, 2002	MAY	NEWA
>A>	AB		100MG	N76110 004	MAY 14, 2002	MAY	NEWA
		TRAMADOL HYDROCHLORIDE						
		TABLET; ORAL						
		ULTRAM						
		+ JOHNSON AND JOHNSON	50MG	N20281 002	MAR 03, 1995	FEB	CAHN
		@	100MG	N20281 001	MAR 03, 1995	FEB	CAHN
>A>		TREPROSTINIL SODIUM						
>A>		INJECTABLE; SUBCUTANEOUS						
>A>		REMODULIN						
>A>		UNITED THERAP	1MG/ML	N21272 001	MAY 21, 2002	MAY	NEWA
>A>			2.5MG/ML	N21272 002	MAY 21, 2002	MAY	NEWA
>A>			5MG/ML	N21272 003	MAY 21, 2002	MAY	NEWA
>A>		+	10MG/ML	N21272 004	MAY 21, 2002	MAY	NEWA
		TRIMETHOBENZAMIDE HYDROCHLORIDE						
		CAPSULE; ORAL						
		TIGAN						
		+ KING PHARMS	300MG	N17531 006	DEC 13, 2001	JAN	NEWA
		INJECTABLE; INJECTION						
		TRIMETHOBENZAMIDE HCL						
		@ STERIS	100MG/ML	N87939 001	DEC 28, 1982	FEB	DISC

		UROFOLLITROPIN						
		INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS						
>A>		BRAVELLE						
>A>	BX +	FERRING	75 IU/VIAL	N21289 001	MAY 06, 2002	MAY	NEWA	
		INJECTABLE; SUBCUTANEOUS						
		FERTINEX						
>D>	+	SERONO	75 IU/AMP	N19415 005	AUG 23, 1996	MAY	CTEC	
>A>	BX +		75 IU/AMP	N19415 005	AUG 23, 1996	MAY	CTEC	
		URSODIOL						
		CAPSULE; ORAL						
		ACTIGALL						
		@ WATSON PHARMS	150MG	N19594 001	DEC 31, 1987	FEB	CAHN	
	AB +		300MG	N19594 002	DEC 31, 1987	FEB	CAHN	
		VALACYCLOVIR HYDROCHLORIDE						
		TABLET; ORAL						
		VALTREX						
		@ GLAXOSMITHKLINE	EQ 500MG BASE	N20487 001	JUN 23, 1995	MAR	DISC	
		@	EQ 1GM BASE	N20487 002	JUN 23, 1995	MAR	DISC	
		VENLAFAXINE HYDROCHLORIDE						
		CAPSULE, EXTENDED RELEASE; ORAL						
		EFFEXOR XR						
>D>	+	WYETH AYERST	EQ 37.5MG BASE	N20699 001	OCT 20, 1997	MAY	CRLD	
>A>			EQ 37.5MG BASE	N20699 001	OCT 20, 1997	MAY	CRLD	
>D>	+		EQ 150MG BASE	N20699 004	OCT 20, 1997	MAY	CRLD	
>A>			EQ 150MG BASE	N20699 004	OCT 20, 1997	MAY	CRLD	
		VERAPAMIL HYDROCHLORIDE						
		CAPSULE, EXTENDED RELEASE; ORAL						
		VERELAN						
	AB +	ELAN DRUG	120MG	N19614 001	MAY 29, 1990	APR	CAHN	
	AB +		180MG	N19614 003	JAN 09, 1992	APR	CAHN	
	AB +		240MG	N19614 002	MAY 29, 1990	APR	CAHN	
	+		360MG	N19614 004	MAY 10, 1996	APR	CAHN	
>A>		VORICONAZOLE						
>A>		INJECTABLE; IV (INFUSION)						
>A>		VFEND						
>A>	+	PFIZER	200MG/VIAL	N21267 001	MAY 24, 2002	MAY	NEWA	
>A>		TABLET; ORAL						
>A>		PFIZER	50MG	N21266 001	MAY 24, 2002	MAY	NEWA	
>A>	+		200MG	N21266 002	MAY 24, 2002	MAY	NEWA	

ACETAMINOPHEN
TABLET, EXTENDED RELEASE; ORAL
ACETAMINOPHEN
COREPHARMA 650MG N76200 001 MAR 19, 2002 MAR NEWA

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
CONTAC 12 HOUR
@ GLAXOSMITHKLINE 8MG;75MG N18099 001 JAN DISC >A>
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE
@ CENT PHARMS 8MG;75MG N18809 001 MAY 07, 1984 FEB DISC >D>

FAMOTIDINE
TABLET; ORAL
FAMOTIDINE
TORPHARM 10MG N75610 001 MAR 12, 2002 MAR NEWA

IBUPROFEN
TABLET; ORAL
IBUPROFEN
PERRIGO 200MG N75995 001 MAR 14, 2002 MAR NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
>A> CAPSULE; ORAL
>A> ADVIL COLD AND SINUS
>A> WYETH CONS 200MG;30MG N21374 001 MAY 30, 2002 MAY NEWA
SUSPENSION; ORAL
CHILDREN'S ADVIL COLD
WYETH CONS 100MG/5ML;15MG/5ML N21373 001 APR 18, 2002 APR NEWA
TABLET; ORAL
IBUPROFEN AND PSEUDOEPHEDRINE HCL
PHARM FORM 200MG;30MG N75588 001 APR 08, 2002 APR NEWA

INSULIN PURIFIED PORK
INJECTABLE; INJECTION
REGULAR PURIFIED PORK INSULIN
@ NOVO NORDISK 100 UNITS/ML N18381 001 FEB DISC

INSULIN SUSP ISOPHANE PURIFIED PORK
INJECTABLE; INJECTION
NPH PURIFIED PORK ISOPHANE INSULIN
@ NOVO NORDISK 100 UNITS/ML N18623 001 FEB DISC

INSULIN ZINC SUSP PURIFIED PORK
INJECTABLE; INJECTION
LENTE
@ NOVO NORDISK 100 UNITS/ML N18383 001 FEB DISC

KETOPROFEN
TABLET; ORAL
KETOPROFEN
PERRIGO 12.5MG N75364 001 FEB 07, 2002 FEB NEWA

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)

	CLAY PARK	5%	N75737	001	MAR 15, 2002	MAR	NEWA
	NOVEX	5%	N75839	001	OCT 01, 2001	MAR	CTNA

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

SUDAFED 12 HOUR

>A>	+	WARNER LAMBERT	120MG	N73585	001	OCT 31, 1991	MAY	CAHN
>D>	+	WARNER WELLCOME	120MG	N73585	001	OCT 31, 1991	MAY	CAHN

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 5 MAY '02

NO MAY 2002 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
May 2002

Generic Name: **albuterol**
Trade Name: NONE ASSIGNED

Designated Indication: *Prevention of paralysis due to spinal cord injury*

Sponsor: MotoGen, Inc.
Address: 3 Pine View Road
Mount Kisco NY 10549

Date Designated: 3/12/2002
Market Approval Date: Not currently Approved

Generic Name: **autologous antigen presenting cells pulsed with autologous tumor Ig idiotype**
Trade Name: Mylovenge

Designated Indication: *Treatment of multiple myeloma*

Sponsor: Dendreon Corporation
Address: 3005 First Avenue
Seattle WA 98121

Date Designated: 4/18/2002
Market Approval Date: Not currently Approved

Generic Name: **autologous tumor-derived gp96 heat shock protein-peptide complex**
Trade Name: Oncophage

Designated Indication: *Treatment of renal cell carcinoma*

Sponsor: Antigenics, Inc.
Address: 34 Commerce Way
Woburn MA 01702

Date Designated: 5/10/2002
Market Approval Date: Not currently Approved

Generic Name: **aztreonam**
Trade Name: NONE ASSIGNED

Designated Indication: *Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis*

Sponsor: Corus Pharma
Address: 2025 First Ave., Suite 800
Seattle WA 98121

Date Designated: 3/12/2002
Market Approval Date: Not currently Approved

Generic Name: **Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2*

Sponsor: Excorp Medical, Inc.
Address: Suite 235
7200 Hudson Blvd.
Oakdale MN 55128

Date Designated: 2/11/2002
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
May 2002

Generic Name: **carbamic acid, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-,ethyl ester**
Trade Name: NONE ASSIGNED
Designated Indication: *Management of cystic fibrosis*
Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc
Address: 900 Ridgebury Road, P.O. Box 368, Ridgefield CT 06877
Date Designated: 1/15/2002
Market Approval Date: Not currently Approved

Generic Name: **clofarabine**
Trade Name: Clofarex
Designated Indication: *Treatment of acute myelogenous leukemia*
Sponsor: Ilex Products, Inc.
Address: 4545 Horizon Hill Blvd., San Antonio TX 78229-2263
Date Designated: 3/14/2002
Market Approval Date: Not currently Approved

Generic Name: **clofarabine**
Trade Name: Clofarex
Designated Indication: *Treatment of acute lymphoblastic leukemia*
Sponsor: Ilex Products, Inc.
Address: 4545 Horizon Hill Blvd., San Antonio TX 78229-2263
Date Designated: 2/7/2002
Market Approval Date: Not currently Approved

Generic Name: **creatine**
Trade Name: Creapure
Designated Indication: *Treatment of amyotrophic lateral sclerosis*
Sponsor: Avicena Group, Inc.
Address: 580 California St., Suite 1600, San Francisco CA 94104
Date Designated: 2/12/2002
Market Approval Date: Not currently Approved

Generic Name: **genetically engineered herpes simplex virus (G207)**
Trade Name: NONE ASSIGNED
Designated Indication: *Tretament of malignant glioma*
Sponsor: MediGene, Inc.
Address: 9880 Campus Point Drive, Suite A, San Diego CA 92121
Date Designated: 4/29/2002
Market Approval Date: Not currently Approved

Generic Name: **homoharringtonine**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment for chronic myelogenous leukemia*
Sponsor: American BioScience, Inc.
Address: 2730 Wilshire Blvd. #110, Santa Monica CA 90403
Date Designated: 2/8/2002
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
May 2002

Generic Name: **human anti-transforming growth factor beta 1 monoclonal antibody**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of systemic sclerosis*
Sponsor: Genzyme Corporation
Address: One Kendall Square
Cambridge MA 02139
Date Designated: 1/11/2002
Market Approval Date: Not currently Approved

Generic Name: **hyaluronic acid**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency*
Sponsor: Exhale Therapeutics, Inc.
Address: 1301 Shoreway Road
Suite 320
Belmont CA 94002
Date Designated: 3/19/2002
Market Approval Date: Not currently Approved

Generic Name: **I(131)-TM-601 (chlorotoxin)**
Trade Name: NONE ASSIGNED
Designated Indication: *treatment of malignant glioma*
Sponsor: TransMolecular, Inc.
Address: 3800 Colonnade Parkway
Suite 240
Birmingham AL 35243
Date Designated: 2/14/2002
Market Approval Date: Not currently Approved

Generic Name: **lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of active chronic pouchitis*
Sponsor: VSL Pharmaceuticals, Inc.
Address: 800 S. Frederick Avenue
Gaithersburg MD 20877
Date Designated: 1/15/2002
Market Approval Date: Not currently Approved

Generic Name: **lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)**
Trade Name: NONE ASSIGNED
Designated Indication: *Prevention of disease relapse in patients with chronic pouchitis*
Sponsor: VSL Pharmaceuticals, Inc.
Address: 800 S. Frederick Ave.
Gaithersburg MD 20877
Date Designated: 1/15/2002
Market Approval Date: Not currently Approved

Generic Name: **lipase, amylase, and protease**
Trade Name: TheraCLEC-Total
Designated Indication: *Treatment of pancreatic insufficiency*
Sponsor: Altus Biologics Inc.
Address: 625 Putnam Avenue
Cambridge MA 02139
Date Designated: 1/23/2002
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
May 2002

Generic Name: **N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of sickle cell disease*

Sponsor: NeuroSearch A/S
Address: 93 Pederstrupvej
DK-2750 Ballerup
Denmark

Date Designated: 5/13/2002
Market Approval Date: Not currently Approved

Generic Name: **nitazoxanide**
Trade Name: Cryptaz

Designated Indication: *Treatment of intestinal giardiasis*

Sponsor: Romark Laboratories, L.C.
Address: 6200 Courtney Campbell Causeway
Suite 880
Tampa FL 33607

Date Designated: 2/14/2002
Market Approval Date: Not currently Approved

Generic Name: **octavalent Psuedomonas aeruginosa O-polysaccaharide-toxin A conjugate**
Trade Name: Aerugen

Designated Indication: *Prevention of Psuedomonas aeruginosa infections in patients with cystic fibrosis*

Sponsor: Orphan Europe
Address: Immeuble "Le Wilson"
70 avenue du General de Gaulle, 92046 Paris
France

Date Designated: 5/16/2002
Market Approval Date: Not currently Approved

Generic Name: **phenylephrine**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of ileal pouch anal anastomosis related fecal incontinence*

Sponsor: S.L.A. Pharma
Address: Unit 3, Hill Farm Industrial Estate
Leavesden, Watford
United Kingdom WD25 7SA

Date Designated: 2/14/2002
Market Approval Date: Not currently Approved

Generic Name: **recombinant human endostatin protein**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of metastatic melanoma*

Sponsor: EntreMed, Inc.
Address: 9640 Medical Center Drive
Rockville MD 20850

Date Designated: 2/21/2002
Market Approval Date: Not currently Approved

Generic Name: **recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3**
Trade Name: SomatoKine

Designated Indication: *Treatment of growth hormone insensitivity syndrome*

Sponsor: Celtrix Pharmaceuticals, Inc. a subsidiary of
Address: 4851 Lake Brook Drive
Glen Allen VA 23060

Date Designated: 5/17/2002
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
May 2002

Generic Name: **retroviral gamma-c cDNA containing vector** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of X linked severe combined immune deficiency disease*

Sponsor: AVAX technologies, Inc.
Address: 9200 Indian Creek Parkway
Building 9, Suite 200
Overland Park KS 66210

Date Designated: 4/29/2002
Market Approval Date: Not currently Approved

Generic Name: **rituximab** Trade Name: Rituxan

Designated Indication: *Treatment of immune thrombocytopenic purpura*

Sponsor: Genentech, Inc.
Address: 1 DNA Way
South San Francisco CA 94080-4990

Date Designated: 3/12/2002
Market Approval Date: Not currently Approved

Generic Name: **S(-)-3-[3-amino-phthalimido]-glutaramide** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of multiple myeloma*

Sponsor: EntreMed Incorporated
Address: 9640 Medical Center Dr.
Rockville MD 20850

Date Designated: 3/14/2002
Market Approval Date: Not currently Approved

Generic Name: **SS1(dsFv)-PE38** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of epithelial ovarian cancer*

Sponsor: NeoPharm, Inc.
Address: 150 Field Drive
Suite 195
Lake Forest IL 60045

Date Designated: 2/11/2002
Market Approval Date: Not currently Approved

Generic Name: **SS1(dsFv)-PE38** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of malignant mesothelioma*

Sponsor: NeoPharm Incorporated
Address: 150 Field Drive
Suite 195
Lake Forest IL 60045

Date Designated: 2/11/2002
Market Approval Date: Not currently Approved

Generic Name: **tinidazole** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of giardiasis*

Sponsor: Presutti Laboratories, Inc.
Address: 1607 N. Douglas Ave.
Arlington Heights IL 60004

Date Designated: 4/18/2002
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
May 2002

Generic Name:	**toralizumab**	Trade Name:	NONE ASSIGNED
Designated Indication:	*Treatment of immune thrombocytopenic purpura*		
Sponsor:	IDEC Pharmaceuticals Corporation	Date Designated:	3/14/2002
Address:	3030 Callan Road San Diego CA 92121	Market Approval Date:	Not currently Approved

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MAY 2002 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA	6352684	NOV 28, 2009			
	021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10	6322819	NOV 27, 2018			
	021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20	6322819	NOV 27, 2018			
	021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30	6322819	NOV 27, 2018			
	020883 001	ARGATROBAN;ARGATROBAN				I-352	APR 03, 2005
	020911 002	BECLOMETHASONE DIPROPIONATE;QVAR 40	6352684	NOV 28, 2009		NP	SEP 15, 2003
						NPP	MAY 10, 2005
	020911 001	BECLOMETHASONE DIPROPIONATE;QVAR 80	6352684	NOV 28, 2009		NP	SEP 15, 2003
						NPP	MAY 10, 2005
>ADD>	021275 001	BIMATOPROST;LUMIGAN	6403649	SEP 21, 2012	U-446		
	020490 001	BRIMONIDINE TARTRATE;ALPHAGAN				NPP	DEC 20, 2004
						PED	JUN 20, 2005
	020613 001	BRIMONIDINE TARTRATE;ALPHAGAN				NPP	DEC 20, 2004
						PED	JUN 20, 2005
	021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P				NPP	DEC 20, 2004
						PED	JUN 20, 2005
	018731 001	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
						PED	JAN 19, 2005
						W	JUL 19, 2004
						W	JAN 19, 2005
	018731 002	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
						PED	JAN 19, 2005
						W	JUL 19, 2004
						W	JAN 19, 2005
	018731 003	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
						PED	JAN 19, 2005
						W	JUL 19, 2004
						W	JAN 19, 2005
	018731 004	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
						PED	JAN 19, 2005
						W	JUL 19, 2004
						W	JAN 19, 2005
	020954 001	BUSULFAN;BUSULFEX	5430057	SEP 30, 2013	U-263	ODE	FEB 04, 2006
			5559148	MAY 24, 2015	U-264	NDF	FEB 04, 2002
			5430057*PED	MAR 30, 2014	U-263	PED	AUG 04, 2002
			5559148*PED	NOV 24, 2015	U-264	PED	AUG 04, 2006
	019835 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
			4525358*PED	DEC 25, 2007			
	019835 002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
			4525358*PED	DEC 25, 2007			
	020346 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
			4525358*PED	DEC 25, 2007			
	020369 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	DEC 09, 2003	U-223		
	020839 001	CLOPIDOGREL BISULFATE;PLAVIX				I-349	FEB 27, 2005

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021165 001	DESLORATADINE;CLARINEX	6100274	JUL 07, 2019			
	075863 001	DESOGESTREL;KARIVA				PC	JUN 04, 2002
	021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6355656	DEC 04, 2015			
	021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6355656	DEC 04, 2015			
	021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6355656	DEC 04, 2015			
	020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	6372760	MAR 31, 2019			
	020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	6372760	MAR 31, 2019			
	021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	6369085	MAY 25, 2018			
	021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	6369085	MAY 25, 2018			
	020655 001	ESTRADIOL;ALORA				I-351	APR 05, 2005
	020655 002	ESTRADIOL;ALORA				I-351	APR 05, 2005
	020655 003	ESTRADIOL;ALORA				I-351	APR 05, 2005
	020655 004	ESTRADIOL;ALORA	5122383	MAY 17, 2011		I-351	APR 05, 2005
			5227169	MAY 17, 2011			
			5212199	MAY 17, 2011			
			5164190	DEC 11, 2010			
	020538 005	ESTRADIOL;VIVELLE-DOT				I-254	AUG 16, 2003
	020538 006	ESTRADIOL;VIVELLE-DOT				I-254	AUG 16, 2003
	020538 007	ESTRADIOL;VIVELLE-DOT				I-254	AUG 16, 2003
	020538 008	ESTRADIOL;VIVELLE-DOT				I-254	AUG 16, 2003
	075753 002	FENOFIBRATE;FENOFIBRATE (MICRONI				PC	SEP 15, 2002
	075753 003	FENOFIBRATE;FENOFIBRATE (MICRONI				PC	SEP 15, 2002
	075442 001	FLECAINIDE ACETATE;FLECAINIDE ACETATE				PC	OCT 28, 2002
	075442 002	FLECAINIDE ACETATE;FLECAINIDE ACETATE				PC	OCT 28, 2002
	075442 003	FLECAINIDE ACETATE;FLECAINIDE ACETATE				PC	OCT 28, 2002
	021345 001	FONDAPARINUX SODIUM;ARIXTRA	4818816	AUG 19, 2003			
	021344 001	FULVESTRANT;FASLODEX				NCE	APR 25, 2007
	020235 001	GABAPENTIN;NEURONTIN	5084479	JAN 02, 2010	U-258	I-354	MAY 24, 2005
			5084479*PED	JUL 02, 2010	U-258		
	020235 002	GABAPENTIN;NEURONTIN	5084479	JAN 02, 2010	U-258	I-354	MAY 24, 2005
			5084479*PED	JUL 02, 2010	U-258		
	020235 003	GABAPENTIN;NEURONTIN	5084479	JAN 02, 2010	U-258	I-354	MAY 24, 2005
			5084479*PED	JUL 02, 2010	U-258		
	020882 001	GABAPENTIN;NEURONTIN				I-354	MAY 24, 2005
	020882 002	GABAPENTIN;NEURONTIN				I-354	MAY 24, 2005
	021129 001	GABAPENTIN;NEURONTIN				I-354	MAY 24, 2005
	020622 001	GLATIRAMER ACETATE;COPAXONE	6342476	MAY 24, 2014	U-441		
			6362161	MAY 24, 2014	U-441		
>ADD>	020305 002	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 20, 2007	U-105		
>ADD>	020125 001	HYDROCHLOROTHIAZIDE;ACCURETIC	4344949	OCT 03, 2002	U-3	NC	DEC 28, 2002
>ADD>			4743450	FEB 24, 2007		PED	JUN 28, 2003
>ADD>			4344949*PED	APR 03, 2003	U-3		
>ADD>			4743450*PED	AUG 24, 2007			
>ADD>	020125 002	HYDROCHLOROTHIAZIDE;ACCURETIC	4743450	FEB 24, 2007			
>ADD>			4344949	OCT 03, 2002	U-3		
>ADD>			4344949*PED	APR 03, 2003	U-3		
>ADD>			4743450*PED	AUG 24, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020125 003	HYDROCHLOROTHIAZIDE;ACCURETIC	4344949	OCT 03, 2002	U-3		
>ADD>			4743450	FEB 24, 2007			
>ADD>			4344949*PED	APR 03, 2003	U-3		
>ADD>			4743450*PED	AUG 24, 2007			
	020818 001	HYDROCHLOROTHIAZIDE;DIOVAN HCT	6294197	JUN 18, 2017	U-3		
	020818 002	HYDROCHLOROTHIAZIDE;DIOVAN HCT	6294197	JUN 18, 2017	U-3		
	020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5153197	OCT 06, 2009	U-3		
			5138069	AUG 11, 2009			
			5608075	MAR 04, 2014			
			5138069*PED	FEB 11, 2010			
			5153197*PED	APR 06, 2010	U-3		
			5608075*PED	SEP 04, 2014			
	020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5138069	AUG 11, 2009			
			5153197	OCT 06, 2009	U-3		
			5608075	MAR 04, 2014			
			5138069*PED	FEB 11, 2010			
			5153197*PED	APR 06, 2010	U-3		
			5608075*PED	SEP 04, 2014			
	020716 001	HYDROCODONE BITARTRATE;VICOPROFEN	6348216	JUN 10, 2017			
	021373 001	IBUPROFEN;CHILDREN'S ADVIL COL				NP	AUG 01, 2003
						PED	FEB 01, 2004
	075874 001	IFOSFAMIDE;IFOSFAMIDE/MESNA KIT				PC	OCT 05, 2002
	075874 002	IFOSFAMIDE;IFOSFAMIDE/MESNA KIT				PC	OCT 05, 2002
>ADD>	020757 001	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011			
>ADD>	020757 002	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011			
>ADD>	020757 003	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011			
	019700 001	KETOROLAC TROMETHAMINE;ACULAR				M-16	FEB 08, 2005
	020811 001	KETOROLAC TROMETHAMINE;ACULAR PRESERVATIVE				M-16	FEB 08, 2005
	021343 001	LEUPROLIDE ACETATE;ELIGARD	5599552	FEB 04, 2014			
			5733950	OCT 03, 2008			
			5739176	OCT 03, 2008			
			4938763	OCT 03, 2008			
			5278201	JAN 11, 2011			
			5324519	OCT 20, 2011			
>ADD>	021088 001	LEUPROLIDE ACETATE;VIADUR	6395292	JAN 30, 2017			
			6375978	DEC 17, 2018			
	020634 001	LEVOFLOXACIN;LEVAQUIN				I-357	APR 08, 2003
	020634 002	LEVOFLOXACIN;LEVAQUIN				I-357	APR 08, 2003
	020634 003	LEVOFLOXACIN;LEVAQUIN				I-305	FEB 02, 2003
						I-357	APR 08, 2003
	020635 001	LEVOFLOXACIN;LEVAQUIN				I-357	APR 08, 2003
	020635 002	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE				I-357	APR 08, 2003
	020635 003	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE				I-357	APR 08, 2003
	020386 001	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009			
			5153197	OCT 06, 2009	U-3		
			5608075	MAR 04, 2014			
			5138069*PED	FEB 11, 2010			
			5153197*PED	APR 06, 2010	U-3		
			5608075*PED	SEP 04, 2014			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020386 002	LOSARTAN POTASSIUM;COZAAR	5153197	OCT 06, 2009	U-3		
		5138069	AUG 11, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U-3		
		5608075*PED	SEP 04, 2014			
020386 003	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009			
		5153197	OCT 06, 2009	U-3		
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U-3		
		5608075*PED	SEP 04, 2014			
019643 002	LOVASTATIN;MEVACOR				PED	AUG 14, 2005
					I-350	FEB 14, 2005
019643 003	LOVASTATIN;MEVACOR				PED	AUG 14, 2005
					I-350	FEB 14, 2005
019643 004	LOVASTATIN;MEVACOR				PED	AUG 14, 2005
					I-350	FEB 14, 2005
076175 001	MEFLOQUINE HYDROCHLORIDE;MEFLOQUINE HCL				PC	NOV 03, 2002
020922 001	MEQUINOL;SOLAGE	6353029	AUG 24, 2020			
020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					W	DEC 15, 2003
					W	JUN 15, 2004
021121 004	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4519801	JUL 12, 2002		NP	AUG 01, 2003
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003	U-372		
		5082668	SEP 16, 2003			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020415 001	MIRTAZAPINE;REMERON				M-18	APR 09, 2005
	020415 002	MIRTAZAPINE;REMERON				M-18	APR 09, 2005
	020415 003	MIRTAZAPINE;REMERON				M-18	APR 09, 2005
	019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE				ODE	OCT 13, 2007
	021260 001	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
	021260 002	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
	021260 003	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
	021260 004	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
	020076 004	NICOTINE;HABITROL				D-71	NOV 12, 2002
	020076 005	NICOTINE;HABITROL				D-71	NOV 12, 2002
	020076 006	NICOTINE;HABITROL				D-71	NOV 12, 2002
	020555 001	NIZATIDINE;AXID AR	4375547	APR 12, 2002			
>ADD>	021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	6395292	JAN 30, 2017			
	021286 001	OLMESARTAN MEDOXOMIL;BENICAR				NCE	APR 25, 2007
	021286 003	OLMESARTAN MEDOXOMIL;BENICAR				NCE	APR 25, 2007
	021286 004	OLMESARTAN MEDOXOMIL;BENICAR				NCE	APR 25, 2007
	019810 001	OMEPRAZOLE;PRILOSEC	4636499*PED	NOV 30, 2005			
			6166213*PED	APR 19, 2019			
	019810 002	OMEPRAZOLE;PRILOSEC	4636499*PED	NOV 30, 2005			
			6166213*PED	APR 19, 2019			
	019810 003	OMEPRAZOLE;PRILOSEC	4636499*PED	NOV 30, 2005			
			6166213*PED	APR 19, 2019			
	020766 001	ORLISTAT;XENICAL	4598089	JUN 18, 2009			
	021285 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
	020553 001	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006			
			5266331	OCT 26, 2007			
			5549912	OCT 26, 2007			
			5508042	APR 16, 2013	U-443		
			5656295	OCT 26, 2007	U-443		
	020553 002	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006			
			5266331	OCT 26, 2007			
			5549912	OCT 26, 2007			
			5508042	APR 16, 2013	U-443		
			5656295	OCT 26, 2007	U-443		
	020553 003	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006			
			5266331	OCT 26, 2007			
			5549912	OCT 26, 2007			
			5508042	APR 16, 2013	U-443		
			5656295	OCT 26, 2007	U-443		
	020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013	U-443		
			5656295	OCT 26, 2007	U-443		
			4970075	AUG 29, 2006			
			5266331	OCT 26, 2007			
			5549912	OCT 26, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020553 005	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006			
			5266331	OCT 26, 2007			
			5549912	OCT 26, 2007			
			5508042	APR 16, 2013	U-443		
			5656295	OCT 26, 2007	U-443		
	020987 001	PANTOPRAZOLE SODIUM;PROTONIX				I-356	APR 19, 2005
	020987 002	PANTOPRAZOLE SODIUM;PROTONIX	4758579	JUL 19, 2005		I-356	APR 19, 2005
	020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR				I-358	FEB 12, 2005
	020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR				I-358	FEB 12, 2005
	020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR				I-358	FEB 12, 2005
	020629 001	PENCICLOVIR SODIUM;DENAVIR	5075445	SEP 24, 2010			
	021302 001	PIMECROLIMUS;ELIDEL	6352998	OCT 26, 2015			
			6352998*PED	APR 26, 2016			
	021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425		
	021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425		
	021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425		
	019898 008	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005			
			5030447	JUL 09, 2008			
			5180589	JUL 09, 2008			
			5622985	APR 22, 2014	U-335		
>ADD>	019885 001	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
>ADD>			4743450	FEB 24, 2007			
>ADD>			5684016	NOV 04, 2014	U-210		
>ADD>			5747504	APR 10, 2005	U-210		
>ADD>			4344949*PED	APR 03, 2003	U-3		
>ADD>			4743450*PED	AUG 24, 2007			
>ADD>			5684016*PED	MAY 04, 2015	U-210		
>ADD>			5747504*PED	OCT 10, 2005	U-210		
>ADD>	019885 002	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
>ADD>			4743450	FEB 24, 2007			
>ADD>			5684016	NOV 04, 2014	U-210		
>ADD>			5747504	APR 10, 2005	U-210		
>ADD>			4344949*PED	APR 03, 2003	U-3		
>ADD>			4743450*PED	AUG 24, 2007			
>ADD>			5684016*PED	MAY 04, 2015	U-210		
>ADD>			5747504*PED	OCT 10, 2005	U-210		
>ADD>	019885 003	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
>ADD>			4743450	FEB 24, 2007			
>ADD>			5684016	NOV 04, 2014	U-210		
>ADD>			5747504	APR 10, 2005	U-210		
>ADD>			4344949*PED	APR 03, 2003	U-3		
>ADD>			4743450*PED	AUG 24, 2007			
>ADD>			5684016*PED	MAY 04, 2015	U-210		
>ADD>			5747504*PED	OCT 10, 2005	U-210		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	019885 004	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
>ADD>			4743450	FEB 24, 2007			
>ADD>			5684016	NOV 04, 2014	U-210		
>ADD>			5747504	APR 10, 2005	U-210		
>ADD>			4344949*PED	APR 03, 2003	U-3		
>ADD>			4743450*PED	AUG 24, 2007			
>ADD>			5684016*PED	MAY 04, 2015	U-210		
>ADD>			5747504*PED	OCT 10, 2005	U-210		
	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2003			
>ADD>	020599 001	RILUZOLE;RILUTEK	5527814	JUN 18, 2013			
	020835 001	RISEDRONATE SODIUM;ACTONEL				D-73	MAY 17, 2005
						D-74	MAY 17, 2005
	020835 002	RISEDRONATE SODIUM;ACTONEL				D-73	MAY 17, 2005
						D-74	MAY 17, 2005
	020272 001	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020272 002	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020272 003	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020272 004	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020272 005	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020272 007	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020272 008	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020588 001	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020864 001	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U-240		
	020864 002	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U-240		
	020865 001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JUN 29, 2012	U-240		
	020865 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JUN 29, 2012	U-240		
	021042 001	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
			6063811	MAY 06, 2017	U-266		
	021042 002	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
			6063811	MAY 06, 2017	U-266		
	021042 003	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
			6063811	MAY 06, 2017			
	021052 001	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
			6063811	MAY 06, 2017	U-266		
	021052 002	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
			6063811	MAY 06, 2017	U-266		
	020658 001	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
	020658 002	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
	020658 003	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
	020658 004	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
	020658 005	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
	020658 006	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
	020658 007	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
	020692 001	SALMETEROL XINAFOATE;SEREVENT				I-348	MAR 22, 2005

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020828 001	SAQUINAVIR;FORTOVASE	6352717	NOV 16, 2019			
			6008228	JUN 06, 2015			
	021209 001	SECRETIN;SECREFLO				NP	APR 04, 2005
						ODE	APR 04, 2009
	019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699*PED	FEB 13, 2013	U-12	I-355	MAY 16, 2005
	019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699*PED	FEB 13, 2013	U-12	I-355	MAY 16, 2005
	019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699*PED	FEB 13, 2013	U-12	I-355	MAY 16, 2005
	019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699*PED	FEB 13, 2013	U-12	I-355	MAY 16, 2005
	019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699*PED	FEB 13, 2013	U-12	I-355	MAY 16, 2005
	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-355	MAY 16, 2005
	020478 001	SEVOFLURANE;ULTANE				M-17	MAR 30, 2004
	020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
			5436272	JUL 25, 2012	U-439		
	020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
			5436272	JUL 25, 2012	U-439		
	020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
			5436272	JUL 25, 2012	U-439		
	020572 001	SODIUM PHENYLBUTYRATE;BUPHENYL	4457942	AUG 20, 2004	U-136		
	020573 001	SODIUM PHENYLBUTYRATE;BUPHENYL	4457942	AUG 20, 2004	U-136		
	021075 001	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5912015	MAR 12, 2012			
	021075 002	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5912015	MAR 12, 2012			
	021075 003	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5912015	MAR 12, 2012			
>ADD>	020604 004	SOMATROPIN RECOMBINANT;SEROSTIM				ODE	AUG 23, 2003
	020677 001	SPARFLOXACIN;ZAGAM	4795751	FEB 04, 2010	U-160		
	020132 001	SUMATRIPTAN SUCCINATE;IMITREX	6368627	MAR 02, 2012	U-444		
	020132 002	SUMATRIPTAN SUCCINATE;IMITREX	6368627	MAR 02, 2012	U-444		
	020132 003	SUMATRIPTAN SUCCINATE;IMITREX	6368627	MAR 02, 2012	U-444		
	017970 001	TAMOXIFEN CITRATE;NOLVADEX	4536516	AUG 20, 2002			
			4536516*PED	FEB 20, 2003			
	017970 002	TAMOXIFEN CITRATE;NOLVADEX	4536516	AUG 20, 2002			
			4536516*PED	FEB 20, 2003			
	019785 001	TECHNETIUM TC-99M SESTAMIBI KIT;CARDIOLITE	4452774	DEC 21, 2004			
	019785 003	TECHNETIUM TC-99M SESTAMIBI KIT;MIRALUMA	4452774	DEC 21, 2004			
>ADD>	020846 001	TERBINAFINE;LAMISIL	4755534	DEC 30, 2006	U-445		
			4680291	JUL 14, 2004	U-445		
	020791 001	TESTOSTERONE;TESTODERM TTS	6348210	NOV 10, 2019	U-440		
	020785 001	THALIDOMIDE;THALOMID	6315720	OCT 23, 2020	U-442		
	020697 001	TOLCAPONE;TASMAR	5236952	JAN 29, 2012			
	020697 002	TOLCAPONE;TASMAR	5236952	JAN 29, 2012			
	021228 001	TOLTERODINE TARTRATE;DETROL LA	5559269	NOV 05, 2013	U-318		
	021228 002	TOLTERODINE TARTRATE;DETROL LA	5559269	NOV 05, 2013	U-318		
	021272 001	TREPROSTINIL SODIUM;REMODULIN					
>ADD>						NCE	MAY 21, 2007
	021272 002	TREPROSTINIL SODIUM;REMODULIN				ODE	MAY 21, 2009
>ADD>						NCE	MAY 21, 2007
						ODE	MAY 21, 2009

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021272 003	TREPROSTINIL SODIUM;REMODULIN				NCE	MAY 21, 2007
>ADD>						ODE	MAY 21, 2009
	021272 004	TREPROSTINIL SODIUM;REMODULIN				NCE	MAY 21, 2007
>ADD>						ODE	MAY 21, 2009
	021289 001	UROFOLLITROPIN;BRAVELLE				NP	MAY 06, 2005
	020550 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX	4957924	JUN 23, 2009			
			5879706	JAN 19, 2016			
			6107302	JAN 19, 2016			
	020550 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX	4957924	JUN 23, 2009			
			5879706	JAN 19, 2016			
			6107302	JAN 19, 2016			
	020593 001	VALPROATE SODIUM;DEPACON				D-72	JAN 24, 2005
	021283 001	VALSARTAN;DIOVAN	6294197	JUN 18, 2017	U-3		
	021283 002	VALSARTAN;DIOVAN	6294197	JUN 18, 2017	U-3		
	021283 003	VALSARTAN;DIOVAN	6294197	JUN 18, 2017	U-3		
	021266 001	VORICONAZOLE;VFEND				NCE	MAY 24, 2007
	021266 002	VORICONAZOLE;VFEND				NCE	MAY 24, 2007
	021267 001	VORICONAZOLE;VFEND				NCE	MAY 24, 2007
	021036 001	ZANAMIVIR;RELENZA	6294572	DEC 15, 2014			
	020789 001	ZONISAMIDE;ZONEGRAN	6342515	DEC 21, 2018	U-438		

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 22ND EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR

REFERENCES

NEW DOSING SCHEDULE

D-71	EIGHT WEEK DOSING REGIMEN
D-72	INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
D-73	ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-74	ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

NEW INDICATION

I-348	LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
I-349	ACUTE CORONARY SYNDROME
I-350	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
I-351	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
I-352	ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
I-353	TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
I-354	MANAGEMENT OF POST HERPETIC NEURALGIA
I-355	PREMENSTRUAL DYSPHORIC DISORDER
I-356	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
I-357	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-358	TREATMENT OF PANIC DISORDER

MISCELLANEOUS EXCLUSIVITY CODES

M-15	LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
M-16	CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
M-17	INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
M-18	INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)

PATENT USE CODES

U-438	TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
U-439	TREATMENT OF OBESITY
U-440	METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
U-441	METHOD OF TREATING MS BY ADMINISTERING COPAXONE
U-442	METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
U-443	MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
U-444	METHOD OF TREATING
U-445	USE AS AN ANTIMYCOTIC AGENT
U-446	TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA

New 22nd Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

22nd EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8392

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

_ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $105.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 40%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐-☐

☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(____) _____
Daytime phone including area code

_____
Purchase Order No. (optional)

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature)

(10/01)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.

Approved drug products with therapeutic equivalence